Investigating the genetic relationship between depression symptoms and Alzheimer's Disease in clinically diagnosed and proxy cases

4

5 Lachlan Gilchrist^{a,b,c}, Thomas P. Spargo^{a,d,e}, Rebecca E. Green^f, Jonathan R.I. Coleman^{b,e}, 6 David M. Howard^b, Jackson G. Thorp^g, Brett Adey^b, Jodie Lord^a, Helena L. Davies^b, Jessica 7 Mundy^b, Abigail ter Kuile^{b,e}, Molly R. Davies^{b,e}, Christopher Hübel^{b,h,i}, Shannon Bristow^{b,e}, Sang Hyuck Lee^{b,e}, Henry Rogers^{b,e}, Charles Curtis^{b,e}, Gursharan Kalsi^{b,e}, Ryan Arathimos^b, 8 9 Anne Corbettⁱ, Clive Ballardⁱ, Helen Brookerⁱ, Byron Creeseⁱ, Dag Aarsland^k, Adam 10 Hampshire¹, Latha Velayudhan^k, Thalia C. Eley^{b,e}, Gerome Breen^{b,e}, Alfredo Iacoangeli^{d,a,e}, 11 Sulev Koks^{c,m}, Cathryn M. Lewis^{b,n}, Petroula Proitsi^{a*} on behalf of the Alzheimer's Disease 12 Neuroimaging Initiative, AddNeuroMed, and GERAD1 Consortium

13

^a Department of Basic and Clinical Neuroscience, King's College London, London, United Kingdom

15 ^b Social, Genetic and Developmental Psychiatry, King's College London, London, United Kingdom

16 ° Perron Institute for Neurological and Translational Science, Perth, Australia

^d Department of Biostatistics and Health Informatics, King's College London, London, United Kingdom

18 • NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust

19 and King's College London, King's College London, London, United Kingdom

20 ^f MRC Unit for Lifelong Health and Aging, University College London, London, United Kingdom

^g Translational Neurogenomics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane,
 Australia

23 h National Centre for Register-based Research, Aarhus BSS Business and Social Sciences, Aarhus

24 University, Aarhus, Denmark

¹Department of Pediatric Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany

26 ^j College of Medicine and Health, University of Exeter, Exeter, United Kingdom

27 ^kOld Age Psychiatry, King's College London, London, United Kingdom

28 Faculty of Medicine, Department of Brain Sciences, Imperial College London, London, United Kingdom

29 ^m Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Australia

30 ⁿ Department of Medical and Molecular Genetics, King's College London, London, United Kingdom

31 32

33 * Corresponding author: Dr. Petroula Proitsi (petroula.proitsi@kcl.ac.uk)

34

35 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract
Depression is a risk factor for Alzheimer's disease (AD), but evidence for their genetic
relationship is mixed. Assessing depression symptom specific genetic associations
may better clarify this relationship.

Using data from the UK Biobank, the GLAD Study and PROTECT, we performed the 41 largest genome-wide meta-analyses (GWAS) of the nine depression symptom items, 42 plus their sum score, on the Patient Health Questionnaire (PHQ-9) (GWAS equivalent 43 N: 224,535–308,421). We assessed global/local genetic correlations and statistical 44 colocalisation between depression phenotypes and AD across six AD GWAS with 45 46 varying proportions of clinical and proxy (family history) case ascertainment. We assessed bi-directional causal associations using Mendelian randomisation (MR) and 47 the predictiveness of depression phenotype polygenic risk scores (PRS) for AD 48 case/control status in three clinical AD cohorts. 49

50

Our GWAS meta-analyses identified 37 genomic risk loci across the ten depression 51 52 symptom phenotypes. Of the 72 global genetic correlation tests conducted between depression/depression symptoms and AD, 20 were significant at p_{FDR}≤ 0.05. Only one 53 54 significant genetic correlation was identified with AD GWAS containing clinical-only cases. Colocalisation was not identified at loci contains local genetic correlation but 55 was identified in the region of transmembrane protein 106B (TMEM106B) between 56 57 multiple depression phenotypes and both clinical-only and clinical+proxy AD. MR and 58 PRS analyses did not vield statistically significant results.

59

Our findings do not demonstrate a causal role of depression/depression symptoms on
AD and suggest that previous evidence of their genetic overlap may be driven by the
inclusion of proxy cases/controls. However, the identification of colocalisation at
TMEM106B warrants further investigation.

- 64
- 65
- 66
- 67

2

68 1. INTRODUCTION

Epidemiological studies suggest that a diagnosis of depression is a risk factor for the
later development of dementia¹⁻⁶, of which Alzheimer's disease (AD) is the most
common form, accounting for approximately 80% of the over 40 million global cases⁷.
Establishing the underlying mechanisms by which depression confers increased risk
for AD offers a pathway by which new interventions might be implemented and the
global dementia burden reduced⁸.

As twin studies have demonstrated, both depression and AD are substantially 75 heritable – approximately 40% and 80% respectively^{9,10}. Further, large-scale genome-76 wide association studies (GWAS) have demonstrated high polygenicity, identifying 77 over 70 genomic risk loci for AD and nearly 200 for depression^{11–17}. It is therefore 78 79 possible that their phenotypic association is in part due to shared genetic 80 architecture. However, results from previous investigations into the genetic overlap between the two disorders have been mixed. For example, some findings indicate 81 non-significant genetic overlap^{18,19}, others a significant – if modest – genetic 82 correlation of ~16-17% and a risk increasing causal effect of depression on AD²⁰⁻²². 83

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-84 5), diagnosis of a major depressive episode requires the presence of at least five of 85 a possible nine symptoms for ≥ 2 weeks, including one of the two cardinal symptoms 86 - depressed mood or anhedonia²³. Potentially hundreds of symptom combinations 87 are possible to meet this diagnosis criteria²⁴⁻²⁶. As such, this heterogeneity poses 88 challenges to researchers seeking to better understand differences in the genetic 89 contribution to depression and its subtypes^{27,28}. However, the decomposition of 90 91 depression into individual symptoms has provided insight into unique patterns of genome-wide significant loci and cross-trait genetic associations, as demonstrated 92 in a recent GWAS of depression symptoms on the Patient Health Questionnaire (PHQ-93 9) by Thorp et al.²⁹. 94

A number of studies suggest that anhedonia may be a better predictor of dementia than depressed mood³⁰⁻³². Further, several depression symptoms, such as appetite changes, psychomotor dysfunction, and sleep disruption are commonly observed in non-depressed dementia patients³³⁻³⁵. Taking this into account alongside the mixed nature of previous findings examining the genetic overlap between depression and AD, it is possible that leveraging depression symptom level genetic information may offer greater insight into the disorders shared genetic architecture.

However, any association between depression and AD must also consider the
 potential influence of differences in case/control ascertainment in AD GWAS. A review
 by Escott-Price et al.³⁶ notes that recent large-scale AD GWAS contain a relatively
 small proportion of clinically ascertained cases/controls, with a large percentage of

cases ascertained by proxy – that is, cases and controls are defined as individuals with and without a self-reported parental history of AD/dementia, respectively. The combination of clinical and proxy samples in AD GWAS meta-analyses has proved an effective way of boosting sample size and variant discovery^{15–17,37}. However, evidence suggests that this has come at the expense of specificity in regard to genomic risk loci and an apparent stagnation in the percentage of variance explained by common variants³⁶. Most importantly for cross-trait analysis, recent studies indicate that the direction of Mendelian Randomisation (MR) causal estimates for AD risk factors on AD can be in the opposite direction depending on whether the AD outcome GWAS contains clinical and proxy cases/controls or is more strictly clinically ascertained^{38–40}.

To address these points, we perform the first and largest genome-wide meta-analyses of PHQ-9 depression symptom items using data from the Genetic Links to Anxiety and Depression (GLAD) Study⁴¹, the PROTECT Study^{42,43} and two questionnaires from UK Biobank (UKB)⁴⁴. We obtained summary statistics from previous large-scale GWAS for clinical¹¹ and broad¹² depression, and six AD GWAS. Specifically, three with clinical+proxy case/control ascertainment¹⁵⁻¹⁷, one with proxy-only³⁷, and two with clinical-only^{14,45}. We used these GWAS to assess the presence, strength and differences in genetic overlap between depression, depression symptoms and AD, with the additional aim of better understanding the influence of different AD case ascertainment strategies on associations.

142 2. METHODS

143 For an analysis flowchart, see Figure 1.



Figure 1: Analysis flowchart for the present study describing the analyses undertaken following genetic and phenotypic quality control (see: Methods) for each of the depression symptom items of the Patient Health Questionnaire (PHQ-9) in each of the four samples – UK Biobank (Mental Health Questionnaire and Experience of Pain Questionnaire), the Genetic Links in Anxiety and Depression (GLAD) Study and the PROTECT Study. GWAS = Genome-wide association analysis: AD = Alzheimer's Disease; MTAG = Multi-trait Analysis of GWAS; FUMA = Functional Mapping and Annotation; LAVA = Local Analysis of [co]Variant Association; ADNI = Alzheimer's Disease Neuroimaging Initiative; PC = genetic principal components

2.1 GWAS in the UK Biobank, GLAD and PROTECT

2.1.1 Patient Health Questionnaire-9 (PHQ-9) phenotypes

The PHQ-9 is a well-validated clinical screening questionnaire used to assess depression symptom severity on nine individual symptoms in the DSM-IV^{46,47}. The severity of each symptom is measured by the self-reported persistence of that symptom over the preceding two weeks on a scale of 0 to 3. Scores of 3 indicate an individual experienced that symptom nearly every day, 2 indicates an individual experienced that symptom more than half the days, 1 indicates an individual experienced that symptom for several days and 0 indicates no experience of that symptom at all. The sum of an individual's scores over all nine items (sum-score) ranges from 0-27. For an overview of the PHQ-9 items and response distribution for each sample, see **Table 1**. Sum-score distributions can be seen in **Supplementary** Table 1.

| 183 |
|-----|
| 184 |
| 185 |
| 186 |

| | PHQ-9 Question: | | | | PHQ-9 Response | | | | | |
|-------------------------------|--|---------------------------------------|--------------------|---|--|--|-------------------------|--|--|--|
| Depression Symptom | How often in the last 2 weeks have you been bothered by any of the following problems? | UK Biobank Data Field (MHQ/EoP) | Cohort | 0 (Not at all) | 1 (Several days) | 2 (more than half the days) | 3 (Nearly every day) | | | |
| | | | UK Biobank (MHQ) | 117045 (81.75%) | 21088 (14.73%) | 2965 (2.07%) | 2073 (1.45%) | | | |
| | | | UK Biobank (EoP) | 116330 (76.07%) | 29743 (19.45%) | HQ-9 Response Everal bys) 2 (more than half the days) 3 (N ever (4.73%) 2965 (2.07%) 2073 (1 ever (4.73%) 2965 (2.07%) 2073 (1 ever (19.45%) 4115 (2.69%) 2744 (1 ever (2.31%) 2502 (16.49%) 2142 (1 ever (19.45%) 4115 (2.69%) 2744 (1 ever (2.31%) 2502 (16.49%) 2142 (1 ever (2.94%) 3860 (2.70%) 3285 (2 ever (2.94%) 3860 (2.70%) 3285 (2 ever (2.94%) 36057 (20.15%) 3413 (2 ever (3.99%) 3057 (20.15%) 3413 (2 ever (3.93%) 3057 (20.15%) 3413 (2 ever (3.93%) 3057 (20.15%) 3413 (2 ever (4.55%) 12466 (3.90%) 10832 (4.24%) 2713 (1.89%) 2121 (1 ever (5.33%) 3258 (2.13%) 2313 (1 ever (3.47%) 116 (1.53%) 77 (1.0 (5.70%) 8978 (2.82%) 6926 (2 ever (8.82%) 2998 (1.9.6%) 2016 (1 ever (4.47%) 2538 (16.73%) 2292 (1 ever | 2744 (1.79%) | | | |
| Anhedonia | Little interest or pleasure in doing things | 20514/120104 | GLAD | Cohort I (Several days) I (Several half the days) Biobank (MHQ) 117045 (81.75%) 21088 (14.73%) 2965 (2.07%) Biobank (EoP) 116330 (76.07%) 29743 (19.45%) 4115 (2.69%) AD 4108 (27.08%) 6429 (42.31%) 2502 (16.49%) OTECT 6194 (81.62%) 1130 (14.89%) 127 (1.67%) Biobank (MQ) 117505 (82.07%) 18521 (12.94%) 3860 (2.70%) Biobank (MQ) 117505 (82.07%) 24352 (14.67%) 5404 (3.53%) AD 4242 (27.96%) 4459 (29.39%) 3057 (20.15%) OTECT 6364 (83.86%) 971 (12.79%) 145 (1.91%) Biobank (MPQ) 117551 (82.07%) 20386 (14.24%) 2713 (1.89%) Biobank (MPQ) 123920 (81.03%) 23441 (15.33%) 3258 (2.13%) AD 4665 (30.75%) 5200 (34.28%) 2891 (19.06%) OTECT 6374 (83.99%) 1022 (13.47%) 116 (1.53%) Biobank (MPQ) 112187 (78.36%) 6516 (18.52%) 2690 (1.88%) Biobank (MHQ) 112004 (77.81%) 28914 (18.91%) 2 | 2142 (14.12%) | | | | | |
| | | | PROTECT | 6194 (81.62%) | 1130 (14.89%) | 127 (1.67%) | 138 (1.82%) | | | |
| | | | Total | 243677 (76.42%) | 58380 (18.31%) | Ponse 2 (more than half the days) 2965 (2.07%) 4115 (2.69%) 2502 (16.49%) 127 (1.67%) 9709 (3.04%) 3860 (2.70%) 5404 (3.53%) 3057 (20.15%) 145 (1.91%) 12466 (3.90%) 2713 (1.89%) 258 (2.13%) 2891 (19.06%) 116 (1.53%) 8978 (2.82%) 2690 (1.88%) 2998 (1.96%) 2538 (16.73%) 92 (1.21%) 8318 (2.61%) 7595 (5.30%) 8820 (5.77%) 3530 (23.27%) 359 (4.73%) 20304 (6.37%) 2878 (2.01%) 3399 (2.22%) 2800 (18.46%) 128 (1.69%) 128 (1.69%) 1292 (0.29%) 3398 (1.24%) 10007 (6.99%) 12245 (8.01%) 2173 (20.91%) 3173 (20.91%) 2595 (8.15%) 3566 (0.40%) 686 (0.45%) 1215 | 7097 (2.23%) | | | |
| | | | UK Biobank (MHQ) | 117505 (82.07%) | 18521 (12.94%) | 3860 (2.70%) | 3285 (2.29%) | | | |
| | | | UK Biobank (EoP) | 121071 (79.17%) | 22432 (14.67%) | 5404 (3.53%) | 4025 (2.63%) | | | |
| Appetite Changes | Poor appetite or overeating | 20511/120108 | GLAD | 4242 (27.96%) | 4459 (29.39%) | 3057 (20.15%) | 3413 (22.50%) | | | |
| | | | PROTECT | 6364 (83.86%) | 971 (12.79%) | 145 (1.91%) | 109 (1.44%) | | | |
| | | | Total | 249182 (78.15%) | 46383 (14.55%) | Q-9 Response 2 (more than half the days) Alf the days) 73% 2965 (2.07%) 4150 (2.69%) 4151 (2.69%) 127 (1.67%) 31%) 9709 (3.04%) 34%) 3860 (2.70%) 5404 (3.53%) 3057 (20.15%) 3057 (20.15%) 12466 (3.90%) 3057 (20.15%) 12466 (3.90%) 33%) 3258 (2.13%) 33%) 22891 (19.06%) 7%) 116 (1.53%) 20%) 2690 (1.88%) 30%) 2891 (19.06%) 7%) 1316 (.73%) 878 (2.82%) 2690 (1.88%) 20%) 2690 (1.88%) 20%) 2538 (16.73%) 20% 2690 (1.88%) 20% 2690 (1.88%) 20% 2690 (1.88%) 20% 2690 (1.88%) 20% 2690 (1.88%) 20% 2690 (1.88%) 20% 2690 (1.88%) 20% 2690 (1.88%) 20% 2690 (1.88%) < | 10832 (3.40%) | | | |
| | | | UK Biobank (MHQ) | 117951 (82.07%) | 20386 (14.24%) | 2713 (1.89%) | 2121 (1.48%) | | | |
| | | | UK Biobank (EoP) | 123920 (81.03%) | 23441 (15.33%) | 3258 (2.13%) | 2313 (1.51%) | | | |
| Concentration Problems | Trouble concentrating on things | 20508/120110 | GLAD | 4665 (30.75%) | 5200 (34.28%) | PHQ-9 Response (Several days) 2 (more than half the days) 3 (14.73%) 2965 (2.07%) 2 3 (14.73%) 2965 (2.07%) 2 3 (14.73%) 2965 (2.07%) 2 3 (19.45%) 4115 (2.69%) 2 3 (19.45%) 127 (1.67%) 2 3 (12.94%) 3860 (2.70%) 2 3 (14.67%) 5404 (3.53%) 2 2 (14.67%) 5404 (3.53%) 2 2 (14.67%) 5404 (3.53%) 2 2 (14.67%) 5404 (3.53%) 2 3 (14.55%) 12466 (3.90%) 2 3 (14.55%) 12466 (3.90%) 2 3 (14.24%) 2713 (1.89%) 2 3 (14.55%) 12466 (3.90%) 2 3 (14.24%) 2891 (19.06%) 2 3 (14.24%) 2713 (1.89%) 2 3 (14.24%) 2938 (1.96%) 2 3 (15.02%) 2690 (1.88%) 2 3 (18.52%) 2690 (1.88%) 2 3 (14.69%) 359 (4.73%) | 2415 (15.92%) | | | |
| | | | PROTECT | 6374 (83.99%) | PHQ-9 Response all) 1 (Several days) 2 (more than half the days) e '5%) 21088 (14.73%) 2965 (2.07%) 20' '5%) 29743 (19.45%) 4115 (2.69%) 27' 6) 6429 (42.31%) 2502 (16.49%) 21' 6) 1130 (14.89%) 127 (1.67%) 133 12%) 58380 (18.31%) 9709 (3.04%) 70' 7%) 22432 (14.67%) 5404 (3.53%) 40' 6) 971 (12.79%) 145 (1.91%) 10' 55%) 46383 (14.55%) 12466 (3.90%) 10' 55%) 46383 (14.55%) 12466 (3.90%) 10' 55%) 46383 (14.55%) 12466 (3.90%) 10' 56%) 2501 (15.33%) 2281 (19.06%) 21' 57%) 40342 (15.33%) 2281 (19.06%) 21' 17%) 20386 (14.24%) 2713 (1.89%) 21' 12%) 50049 (15.70%) 8978 (2.23%) 69' 6(5) 1022 (13.47%) 116 (1.53%) 7' < | 77 (1.01%) | | | | |
| | | | Total | 252910 (79.32%) | 50049 (15.70%) | 8978 (2.82%) | 6926 (2.17%) | | | |
| | | | UK Biobank (MHQ) | 112187 (78.36%) | 26516 (18.52%) | 2690 (1.88%) | 1778 (1.24%) | | | |
| | Feeling down, depressed, or hopeless | 20510/120105 | UK Biobank (EoP) | 119004 (77.81%) | 28914 (18.91%) | 2998 (1.96%) | 2016 (1.32%) | | | |
| Depressed Mood | | | GLAD | 3595 (23.70%) | 6746 (44.47%) | 2538 (16.73%) | 2292 (15.11%) | | | |
| | | | PROTECT | It D (Not at all) I (Several days) Z (more than half the days) S all MHQ 117045 (81.75%) 21088 (14.73%) 2965 (2.07%) 207. EoP) 116330 (76.07%) 29743 (19.45%) 4115 (2.69%) 274. 4108 (27.08%) 6429 (42.31%) 2502 (16.49%) 214. 6194 (81.62%) 1130 (14.89%) 127 (1.67%) 138 6194 (81.62%) 1130 (14.29%) 3860 (2.70%) 328 EoP) 121071 (79.17%) 22432 (14.67%) 5404 (3.53%) 402 4242 (27.96%) 4459 (29.39%) 3057 (20.15%) 341 6364 (83.86%) 971 (12.79%) 145 (1.91%) 109 249182 (78.15%) 46383 (14.52%) 2713 (1.89%) 231 6365 (30.75%) 5200 (34.28%) 2891 (19.06%) 241 6374 (83.99%) 102 (13.47%) 116 (1.53%) 77 (25910 (79.32%) 50049 (15.70%) 8978 (2.82%) 692 MHQ) 112137 (78.36%) 26516 (18.52%) 2690 (1.88%) 177 (EoP) 1190 | 60 (0.79%) | | | | | |
| | | | Total | 240894 (75.55%) | 63505 (19.92%) | 8318 (2.61%) | 6146 (1.93%) | | | |
| | | | UK Biobank (MHQ) | 71903 (50.39%) | 56170 (39.23%) | 7595 (5.30%) | 7503 (5.24%) | | | |
| Fatigue | Feeling tired or having little energy | | UK Biobank (EoP) | 74733 (48.87%) | 61571 (40.26%) | 8820 (5.77%) | 7808 (5.11%) | | | |
| | | 20519/120107 | GLAD | 1335 (8.80%) | 4971 (32.77%) | 3530 (23.27%) | 5335 (35.17%) | | | |
| | | | PROTECT | 3715 (48.95%) | Construction Construction Construction Construction Construction Construction Construction | 351 (4.63%) | | | | |
| | | | Total | 151686 (47.57%) | 125876 (39.48%) | 20304 (6.37%) | 20997 (6.58%) | | | |
| | | | UK Biobank (MHQ) | 116091 (81.09%) | 21503 (15.02%) | 2878 (2.01%) | 2699 (1.89%) | | | |
| | Feeling bad about yourself – or that you are | | UK Biobank (EoP) | 123702 (80.89%) | 22756 (14.88%) | 3399 (2.22%) | 3075 (2.01%) | | | |
| Feelings of Inadequacy | a failure or have let yourself or your family | 20507/120109 | GLAD | 3986 (26.27%) | 5131 (33.82%) | 2800 (18.46%) | 3254 (21.45%) | | | |
| | down | | | 6095 (80.31%) | 1260 (16.60%) | 128 (1.69%) | 106 (1.40%) | | | |
| | | | | 249874 (78.36%) | 50650 (15.88%) | 9205 (2.89%) | 9134 (2.86%) | | | |
| | Moving or speaking so slowly that other | | UK Biobank (IVIHQ) | 135592 (94.71%) | 5805 (4.05%) | 1025 (0.72%) | 749 (0.52%) | | | |
| Davahan atar Changas | people could have noticed, or the oppisite - | 20518/120111 | | 141662 (92.63%) | 8285 (5.42%) | 1076 (1.10%) | 1309 (0.86%) | | | |
| Psychomotor Changes | being so fidity or restless that you have | 20518/120111 | GLAD | 9932 (05.47%) | 3254 (21.45%) | 1215 (8.01%) | 770 (5.08%) | | | |
| | been moving around a lot more than usual | | Total | 7505 (97.02%) | 102 (2.40%) | 22 (0.29%) | 22 (0.29%) | | | |
| | | | | 72210 (51 14%) | 17320 (3.378) | 10007 (6.00%) | 11000 (7.60%) | | | |
| | | | UK Biobank (FoP) | 70700 (46 20%) | 56055 (37 24%) | 10007 (0.33%) | 12033 (8.46%) | | | |
| Sleen Problems | Trouble falling asleep or staying asleep, or | 20517/120106 | | 2577 (16 99%) | 5043 (33 24%) | 3173 (20.91%) | 4378 (28 86%) | | | |
| Siceptroblems | sleeping too much | 20317/120100 | PROTECT | 3708 (48 86%) | 2749 (36 22%) | 570 (7 51%) | 562 (7 41%) | | | |
| | | | Total | 150303 (47,14%) | 113683 (35 65%) | 110 (11.35%) 7 8978 (2.82%) 69 2690 (1.88%) 17 2998 (1.96%) 22 2538 (16.73%) 27 92 (1.21%) 60 8318 (2.61%) 61 7595 (5.30%) 75 3530 (23.27%) 53 359 (4.73%) 20 2878 (2.01%) 20 2878 (2.01%) 20 2800 (18.46%) 33 128 (1.69%) 11 9205 (2.89%) 92 1025 (0.72%) 74 1676 (1.10%) 12 1215 (8.01%) 11 1215 (8.01%) 12 10007 (6.99%) 12 12245 (8.01%) 12 3173 (20.91%) 4 570 (7.51%) 55 25995 (8.15%) 2 | 28882 (9.06%) | | | |
| | | | UK Biobank (MHO) | 137381 (95.96%) | 4801 (3.35%) | 566 (0.40%) | 423 (0.30%) | | | |
| | | 20513/120112 | UK Biobank (FoP) | 146843 (96.02%) | 4880 (3.19%) | 686 (0.45%) | 523 (0.34%) | | | |
| Suicidal Thoughts | Thoughts you would be better off dead or of | | GLAD | 9116 (60.09%) | 3713 (24,47%) | 1215 (8.01%) | 1127 (7.43%) | | | |
| Sultiuai HIUUgiits | hurting yourself in some way | | PROTECT | 7392 (97.40%) | 172 (2.27%) | 13 (0.17%) | 12 (0.16%) | | | |
| | | | Total | 300732 (94.31%) | 13566 (4.25%) | 2480 (0.78%) | 2085 (0.65%) | | | |
| 107 | | | | | | | | | | |

187

Table 1: Patient Health Questionnaire (PHQ-9) derived depression symptom phenotypes, their

189 corresponding question on the PHQ-9, and the distribution and percentage of responses for each of

190 *the four samples on which genome-wide association analysis was performed.*

191

192

193 2.1.2 Study population

In each GWAS sample, individuals were only retained if they had reported European
ancestry and had provided a valid response to all PHQ-9 items. Individuals were
excluded if they had reported a previous professional diagnosis of schizophrenia,
psychosis, mania, hypomania, bipolar, or manic depression (UKB Field ID: 20544) or
a previous prescription of medication for a psychotic experience (UKB Field ID:
20466).

200 2.1.3 GWAS software

All GWAS were conducted using REGENIE v3.1.3⁴⁸. In step one of REGENIE, ridge 201 202 regression is applied to a subset of quality controlled (QC'd) variants to fit, combine and decompose a set of leave-one-chromosome-out (LOCO) predictions. QC for step 203 one was undertaken using PLINK v1.9⁴⁹. In step two, imputed variants are tested for 204 association with the phenotype. LOCO predictions from step one are included as 205 covariates to control for proximal contamination. For all GWAS, genotyping batch, 206 sex, age, and age-squared were included as covariates, as were the maximum 207 available genetic principal components (PCs) for GLAD (10 PCs) and PROTECT (20 208 209 PCs) to control for population stratification. For the UK Biobank analyses, 16 PCs were 210 included as recommended by Privé et al.⁵⁰. Assessment centre was also included as 211 a covariate for UK Biobank analyses.

A total of 40 GWAS were conducted for the meta-analyses – one for each of the nine PHQ-9 depression symptom phenotypes as well as the sum-score across all nine items in each of the four samples. To maximise statistical power, PHQ-9 phenotypes were treated as continuous (ranging 0-3 for individual items and 0-27 for the sum score) and analysed using linear regression. GWAS were restricted to the autosomes.

218

2.1.4 GWAS: UK Biobank (UKB)

UKB is a large-scale biomedical database and research resource consisting of ~500,000 individuals with data across a broad range of phenotypes, including mental health outcomes⁴⁴. Individuals in UKB have been genotyped on the custom UK
Biobank Axiom or UKBiLEVE arrays, with imputed data available for ~90 million variants imputed with IMPUTE2 using the Haplotype Reference Consortium (HRC)⁵¹ and combined UK10K + 1000 Genomes Phase 3 reference panels⁵².

UKB participants have completed the PHQ-9 in two online surveys. In total, 157,345 individuals provided responses as part of the Mental Health Questionnaire (UKB-MHQ) (Category: 136) between 2016 and 2017, and 167,199 individuals had provided responses as part of the Experience of Pain Questionnaire (UKB-EoP) (Category: 154) between 2019 and 2020.

After filtering for self-reported European ancestry, valid PHQ-9 responses, and 230 231 previous diagnosis/prescription exclusions, 144,630 (UKB-MHQ) and 155,027 (UKB-232 EoP) individuals remained prior to genetic QC for REGENIE. In step one, single-233 nucleotide polymorphisms (SNPs) with a call rate > 98%, minor allele frequency (MAF) > 1%, and Hardy-Weinberg equilibrium test p > 1x10⁻⁸ were retained, as were 234 235 individuals with variant missingness < 2%, no unusual levels of heterozygosity, and 236 not mismatched on sex. Individuals were retained if they were determined to be of 237 European ancestry based on 4-means clustering on the first two principal 238 components.

For the final GWAS analyses, 143,171 (mean age [SD] = 63.70 [7.68]; %female = 56.38%) and 152,932 (mean age [SD] = 65.95 [7.63]; %female = 56.57%) individuals proceeded from the MHQ and EoP questionnaires respectively. Of these, 108,601 individuals had provided responses on both questionnaires. In step two, a total of 9,746,698 imputed variants were retained with MAF ≥ 0.01 and imputation INFO score ≥ 0.7 .

245

2.1.5 GWAS: Genetic Links to Anxiety and Depression (GLAD) Study

The GLAD study has the specific goal of recruiting a large cohort of re-contactable
individuals with anxiety or depression into the National Institute for Health and Care
Research (NIHR) Mental Health BioResource with genetic, environmental and
phenotypic data collected⁴¹. Genotyping for GLAD was conducted using the UK
Biobank v2 Axiom array and imputed using the TopMed imputation pipeline⁵³.

After filtering for self-reported European ancestry, valid PHQ-9 responses, and 251 252 previous diagnosis/prescription exclusions, 15,472 individuals remained prior to genetic QC for REGENIE step one. Genotype data was provided by the study team 253 and had been filtered to retain SNPs with a genotype call rate > 95%, MAF > 1%, 254 Hardy-Weinberg equilibrium test $p > 1 \times 10^{-10}$, and individuals with genotype 255 256 missingness < 5%. Individuals were additionally excluded if they had unusual levels 257 of heterozygosity, mismatched on sex and of non-European ancestry based on 4means clustering. A total of 15,171 individuals (mean age [SD] = 39.27 [14.61]; 258 259 % female = 78.30%) were retained for the final analysis. In step two, a total of 13,979,187 imputed variants with MAF \geq 0.001 and INFO \geq 0.7 were analysed. 260

261 2

2.1.6 GWAS: PROTECT Study

PROTECT is an online registry of ~25,000 UK-based individuals that aims to track
cognitive health in older adults. Individuals were only considered eligible for inclusion
in PROTECT if they were older than 50, had no previous dementia diagnosis and had
internet access. Genetic data are available alongside phenotypic data for ~10,000 of
the participants. These individuals were genotyped on the Illumina Infinium Global

267 Screening Array and imputed on the 1000 Genomes reference panel⁵⁴ using the
268 Michigan imputation server and genotype phasing using Eagle.

After filtering for self-reported European ancestry, valid PHQ-9 responses, and previous diagnosis/prescription exclusions, 7,589 individuals remained for genetic QC for step one of REGENIE. Genetic data in PROTECT had been previously QC'd prior to imputation to only retain individuals and variants with a call rate > 98%, Hardy-Weinberg equilibrium test p > 0.00001 and excluding unusual heterozygosity⁴². Variants used in step one were down-sampled from the imputed data using a snplist from the Illumina Infinium Global Screening Array provided by the PROTECT investigators. Variants were retained if they had MAF > 1%. After mismatched sex and 4-means clustering ancestry exclusions, a total of 7,589 individuals (mean age [SD] = 61.96 [7.07]; %female = 75.13%) proceeded to step two. In step two, 9,388,534 imputed variants with MAF \geq 0.001 and imputation INFO score \geq 0.7 were analysed.

301 2.2 GWAS summary statistics

An overview of additional summary statistics obtained for this study can be seen inTable 2.

| Phenotype (Original GWAS) | Excluded Samples | Cases (% Clinical) | Controls (% Clinical) | Total | SNP h2 (SE) |
|--------------------------------------|---------------------|-----------------------|--------------------------|---------|----------------|
| Depression GWAS | | | | | |
| Broad Depression | | 170,756 | 329,443 | | 0.0798 |
| (Howard et al. (2019)) | 23andMe | (25.3%) | (29.0%) | 500,199 | (0.003) |
| Clinical Depression | UK Biobank; | 45,591 | 97674 | | 0.1012 |
| (Wray et al. (2018)) | 23andMe | (100%) | (100%) | 143,261 | (0.007) |
| Alzheimer's Disease GWAS | | | | | |
| Clinical + Proxy AD | | 85,934 | 401,577 | | 0.0306 |
| (Bellenguez et al. (2022) (Stage 1)) | N/A | (45.5%) | (14.0%) | 487,511 | (0.003) |
| Clinical + Proxy AD | | 86,531 | 676,386 | | 0.0237 |
| (Wightman et al. (2021)) | 23andMe | (46.1%) | (26.1%) | 762,917 | (0.004) |
| Clinical + Proxy AD | | 71,880 | 383,378 | | 0.0234 |
| (Jansen et al. (2019)) | N/A | (33.5%) | (14.4%) | 455,258 | (0.003) |
| Proxy-only AD | | 42,035 | 272,243 | | 0.0165 |
| (Marioni et al. (2018)) | IGAP | (0%) | (0%) | 314,278 | (0.003) |
| Clinical-only AD | UK Biobank; | 39,918 | 358,140 | | 0.0431 |
| (Wightman et al. (no UKB) (2021)) | 23andMe | (100%) | (29.1) | 398,058 | (0.008) |
| Clinical-only AD | | 21,982 | 41,944 | | 0.068 |
| (Kunkle et al. (2019) (Stage 1)) | N/A | (100%) | (86.2%) | 63,926 | (0.011) |

304

305 Table 2: An overview of previously conducted genome-wide association studies for depression and
306 Alzheimer's disease used in this study. Heritability estimates were calculated naively on the liability
307 scale from these standardised summary statistics using Linkage Disequilibrium Score Regression
308 (LDSC), taking a population prevalence of 15% for depression and 5% for Alzheimer's disease.

309

310

2.2.1 Clinical and broad depression

To examine potential differences in genetic overlap with AD between depression as 311 a disorder compared to individual depression symptoms, summary statistics for two 312 313 previously conducted GWAS of clinical and broad depression were obtained from Consortium 314 the Psychiatric Genomics (PGC) (https://pgc.unc.edu/for-315 researchers/download-results/). For clinical depression, we used a subsample of the 316 Major Depressive Disorder (MDD) GWAS by Wray et al.¹¹ that excluded samples from the UKB and 23andMe, and contained only individuals for whom case ascertainment 317 was defined through structured diagnostic interview or electronic health records. For 318 319 the broad definition depression GWAS, we used a subsample of the depression 320 GWAS by Howard et al.¹², which also excluded samples from 23andMe. In addition

to clinical cases and controls used by Wray et al.¹¹, this broad depression GWAS 321 included individuals in the UKB for whom case-control ascertainment was based on 322 self-reported responses to the questions "Have you ever seen a general practitioner 323 324 for nerves, anxiety tension or depression?" and "Have you ever seen a psychiatrist 325 for nerves anxiety, tension or depression?".

326

2.2.2 Alzheimer's disease

327 Summary statistics were obtained from six previously conducted AD GWAS: three 328 with proxy+clinical, one with proxy-only and two with clinical-only case 329 ascertainment. All three of the proxy+clinical AD GWAS – Bellenguez et al.¹⁷, Wightman et al.¹⁶ and Jansen et al.¹⁵ – and the proxy-only AD GWAS – Marioni et al.³⁷ 330 - used data from the UKB for proxy AD samples. 331

332 There are some key differences in the way these AD GWAS define proxy cases 333 and controls. Bellenguez et al.¹⁷ define proxy cases/controls as a binary phenotype, 334 whereby individuals reporting a parent with AD or dementia are considered cases and those reporting no parental history are considered controls. Wightman et al.¹⁶ 335 and Jansen et al.¹⁵ instead define proxy cases/control as a continuous phenotype, 336 337 summing the number of parents an individual has reported with dementia and downweighting unaffected parents by their age (or age of death). 338

For the proxy-only Marioni et al.³⁷ GWAS, summary statistics were obtained 339 from a meta-analysis of paternal and maternal AD. Here, proxy phenotyping was 340 based on the self-report of either maternal or paternal AD, including the parent's age 341 342 at time of reporting/age of death as a covariate.

Summary statistics from a clinical-only subsample of the GWAS by Wightman 343 344 et al. that excluded proxy cases/controls from the UKB⁴⁵ were obtained from the authors. Summary statistics for a final clinical-only AD GWAS were obtained from 345 Stage 1 of the GWAS by Kunkle et al.¹⁴. 346

347

2.3 Summary statistic standardisation

Summary statistics from all 40 depression symptom GWAS, the two depression 348 GWAS and the six AD GWAS, were standardised using the MungeSumstats⁵⁵ in R 349 350 version 4.2.1. Using dbSNP 141 and the BSgenome. Hsapiens. 1000genomes. hs37d5 351 reference genome, missing rsIDs were corrected, duplicates and multi-allelic variants 352 removed, effect alleles and the direction of their effects aligned to the reference 353 genome, and variants filtered at INFO score ≥ 0.7 and MAF ≥ 0.01 . The GLAD Study and Bellenguez et al.¹⁷ summary statistics were lifted over from GRCh38 to GRCh37. 354

2.4 SNP heritability 355

SNP heritability (h^2_{SNP}) estimates were calculated for all GWAS used in this 356 study with Linkage Disequilibrium Score Regression (LDSC)^{56,57}. Briefly, LDSC 357 358 calculates h_{SNP}^2 by regressing the effect sizes from GWAS summary statistics on their

LD score as computed in a reference panel – in this case HapMap3 variants contained within the European sample of 1000 Genomes Phase 3. Liability scale h^2_{SNP} was calculated naively from the standardised depression GWAS and AD GWAS using a 15% and 5% population prevalence respectively^{11,16}. Heritability *Z*-scores were calculated for all phenotypes by dividing the h^2_{SNP} estimates by their standard error.

364

2.5 GWAS meta-analysis of depression symptoms

To leverage the maximum genetic information available controlling for the 365 366 sample overlap between the UKB-MHQ and UKB-EoP samples, REGENIE output for each PHQ-9 phenotype from the UKB-EoP, GLAD Study and PROTECT were first 367 subject to Inverse Variance Weighted (IVW) meta-analysis using METAL⁵⁸. All 368 available variants were included, for a total of 8,425,618 (N = 175,692). Multi-trait 369 370 Analysis of GWAS (MTAG)⁵⁹ v1.0.8 was then used to meta-analyse the METAL output 371 with the UKB-MHQ sample. While MTAG is commonly used for the joint genetic 372 analysis of multiple traits or multiple measurements of the same trait, by assuming the 373 heritability of included phenotypes are equal (--equal-h2) and their genetic correlation 374 is one (--perfect-gencov), MTAG performs an IVW meta-analysis of the same measures of the same trait, accounting for sample overlap using the cross-trait 375 376 intercept from LDSC^{56,57}. Heritability estimates for all samples, plus the METAL meta-377 analysis, are in Supplementary Table 2. Genetic correlations between the UKB-MHQ and METAL GWAS are in Supplementary Table 3. For greater detail on the IVW 378 function of MTAG, see the online methods of the original MTAG paper⁵⁹. A total of 379 380 8,196,874 SNPs with MAF > 0.01 were present for MTAG analysis.

This MTAG function provides one set of summary statistics and two GWASequivalent sample sizes – one for each original sample included. A single, weighted GWAS-equivalent *N* was obtained for each PHQ-9-MTAG GWAS, using the following formula;

- 385
- 386

$$N(final) = \frac{(N_1(pre)*N_1(post)) + (N_2(pre)*N_2(post))}{N_1(pre) + N_2(pre)}$$

387

where N_1 and N_2 represents the UKB-MHQ and METAL GWAS respectively, *pre* is the mean sample size prior to inclusion in MTAG and *post* is the GWASequivalent sample estimated by MTAG following analysis.

391

2.6 Genomic risk loci and gene annotation

392 GWAS meta-analysis results were annotated using FUMA GWAS⁶⁰ v3.1.6a. Genome-393 wide significance was set at $p \le 5e-8$. Lead variants at genomic risk loci were defined 394 by clumping all variants correlated at $r^2 > 0.1$ 250kb either side. Clumping was 395 performed using the European sample of the 1000 Genomes Phase 3 reference

panel. Lead variants were mapped to genes within 10kb using positional mapping
and eQTLs from four brain (BrainSeq⁶¹, PsychENCODE⁶², CommonMind⁶³, and
BRAINEAC⁶⁴) and five blood (BloodeQTL⁶⁵, BIOS⁶⁶, eQTLGen cis and trans⁶⁷, Twins
UK⁶⁸ and xQTLServer⁶⁹) eQTL datasets, alongside all 54 tissue type eQTLs from GTEx
v8 (https://gtexportal.org/home/tissueSummaryPage).

401

2.7 Genetic correlations

402 Genetic correlation can be understood as the genome-wide correlation of genetic
403 effects between two phenotypes, and as such can be viewed as an estimate of
404 pleiotropy⁷⁰.

405 Genetic correlations were calculated between each depression phenotype and the six AD GWAS using High Definition Likelihood v1.4.1 (HDL)⁷¹. HDL extends 406 the LDSC framework by leveraging LD information from across the whole LD 407 408 reference panel through eigen decomposition, thus shrinking standard errors and improving precision. A pre-computed eigenvector/value LD reference panel 409 410 calculated from 335,265 individuals of European ancestry in the UKB was obtained via the HDL GitHub (https://github.com/zhenin/HDL/wiki/Reference-panels). This 411 reference panel was calculated using 1,029,876, imputed, autosomal HapMap3 412 413 SNPs, with bi-allelic SNPs outside the MHC region, MAF > 5%, a call rate > 95% and 414 INFO > 0.9 retained.

415

2.8 Local genetic correlations

Local genetic correlation assesses the correlation of genetic effects between two
phenotypes in specific region of the genome. It provides a more refined examination
of the genetic overlap between two phenotypes, allowing for the identification of key
regions driving shared genetic architecture.

LAVA⁷² was used to assess regions of local genetic correlation between each 420 depression phenotype and the six AD GWAS across 2495 semi-independent, pre-421 defined LD-blocks of at least 2500 base pairs (https://github.com/josefin-422 423 werme/LAVA). Loci-specific heritability estimates were calculated for each phenotype for each block. If both a depression phenotype and an AD GWAS showed 424 425 significant local heritability at a specific locus (Bonferroni corrected p-value \leq 2e-5 426 (0.05/2495)), bivariate local genetic correlation was tested. Bivariate results were 427 considered significant at $p_{\text{EDR}} \leq 0.05$ correcting for the total number of bivariate tests. Sample overlap was accounted for using an LDSC intercept matrix. Analysis was 428 restricted to the 5,531,969 non-strand-ambiguous variants shared across all GWAS 429 430 summary statistics and on the European ancestry 1000 Genomes Phase 3 reference 431 panel.

- 432
- 433

434 **2.9 Colocalisation**

435 Colocalisation using COLOC is a Bayesian statistical method to assess the
436 probability of two phenotypes sharing a causal variant in a pre-defined genomic
437 region.

Within the colocalisation framework, posterior probability is assessed for fivehypotheses:

440

441 H_0 : There is no causal variant in the region for either phenotype

- 442 H_1 : There is a causal variant in the region for the first phenotype
- 443 H₂: There is a causal variant in the region for the second phenotype
- 444 H₃: Distinct causal variants for each trait in the region
- 445 H₄: Both traits share a causal variant.
- 446

Colocalisation analysis was conducted using the COLOC-reporter pipeline⁷³ 447 (https://github.com/ThomasPSpargo/COLOC-reporter). COLOC-reporter extracts 448 variants in user-defined genomic regions and calculates the LD matrix for this region 449 from a user-defined reference panel. It then harmonises the summary statistics to 450 451 match the allele order of the reference panel, flipping effect directions accordingly. Observed versus expected Z-scores are assessed using the diagnostic tools 452 provided in the susieR R package⁷⁴. Z-score outliers are omitted. Following this QC, 453 Sum of Single Effects (SuSiE) fine-mapping⁷⁴ is conducted to identify 95% credible 454 sets in these regions for each phenotype. Identification of credible sets in both 455 456 phenotype allows for the relaxation of the single causal variant assumption. All 457 possible credible sets are then assessed pairwise for shared signal between phenotypes, improving resolution for colocalisation inference in regions containing 458 multiple signals⁷⁵. Should no 95% credible set be identified or only identified for one 459 phenotype, colocalisation under the single causal variant assumption is performed 460 461 using the *coloc.abl*⁷⁶. A posterior probability \geq 80% for H₄ was considered evidence of colocalisation between two phenotypes (PP.H₄ \ge 0.8). The SuSiE model assumed 462 463 at most 10 causal variants (L = 10) per credible set. We used default priors.

Trait pairs with LAVA correlations significant at $p_{\text{FDR}} \leq 0.05$ were passed to COLOC-reporter. Where the same depression phenotype showed nominally significant local genetic correlation at the same locus but with different AD GWAS, these phenotype pairs were included as a sensitivity analysis. Regions +/-250kb (r² ≥ 0.1) from lead variants at genome-wide significant loci from the MTAG-PHQ-9, broad and clinical depression GWAS were also examined for evidence of colocalisation with the 6 AD GWAS.

471

472 **2.10 Mendelian randomisation (MR)**

473 MR is a statistical method that uses genetic variants associated with an exposure as 474 instrumental variables to assess the causal effect of that exposure on an outcome of 475 interest⁷⁷. Two Sample MR framework estimates the causal relationships between an exposure and outcome using GWAS summary statistics. Valid MR instruments are 476 defined by three key assumptions: (1) relevance – IVs are strongly associated with 477 478 the exposure of interest; (2) independence - there are no confounders in the association between IVs and the outcome of interest; and (3) exclusion restriction -479 480 instruments are not associated to the outcome other than via the exposure, for 481 example through horizontal pleiotropy⁷⁷.

Sample overlap is a known source of bias in Two Sample MR⁷⁸. Given the
likelihood of sample overlap between the depression phenotypes and the AD GWAS
containing proxy cases/controls due to participants from the UKB, MR analysis was
primarily conducted using Causal Analysis Using Summary Effect estimates
(CAUSE)⁷⁹ v1.2.0. CAUSE is a Bayesian MR method robust to sample overlap,
correlated and uncorrelated pleiotropy, also avoiding exclusion restriction
assumption violations⁸⁰.

In CAUSE, the presence of a significant causal effect, γ , is derived by comparing the expected log pointwise posterior density (ELPD) of a sharing model with γ fixed to zero to a causal model where γ is a free parameter for a one-tailed pvalue test. The posterior median of γ describes the causal effect estimate and is reported alongside its 95% credible intervals. CAUSE uses a larger set of instruments that traditional MR methods. As such, clumping was performed with the default setting at r² ≥ 0.01 and a *p*-value ≤ 0.001 within a 10,000kb window.

Causal estimates were also calculated using the traditional IVW method. IVW
estimates are biased by the presence of horizontal pleiotropy⁸¹. Sensitivity analyses
were therefore conducted using MR-Egger, weighted-median and weighted-mode
MR. These methods allow for varying degrees of pleiotropy while providing unbiased
causal estimates⁸²⁻⁸⁴. MR-PRESSO⁸⁵ was also implemented. MR-PRESSO identifies
and excludes outlying instruments based on their contribution to heterogeneity and
provides a corrected causal estimate.

Pleiotropy was assessed using the MR-Egger intercept test⁸⁶ (significant pleiotropy: *p* ≤ 0.05). Heterogeneity tests were also conducted for IVW and MR-Egger estimates using their respective Cochran's Q test⁸⁷ (significant heterogeneity: *p*-value ≤ 0.05). Instrument strength was calculated via the minimum and mean F-statistic (recommended F-statistic ≥ 10)⁸⁸ (β²/SE²). I² was calculated to ensure measurement error was sufficiently low so as to ensure validity of results from MR-Egger (recommended I² ≥ 0.90)⁸⁹.

510 For IVW-MR, MR-Egger, weighted-median and weighted-mode MR, 511 instruments clumped at a $r^2 \ge 0.001$ and a *p*-value $\le 5e-8$ within 10,000kb. Where no 512 instruments were available at $p \le 5e-8$ or where < 5 instruments were available, a *p* 513 $\le 5e-6$ threshold was used.

For all analyses, instruments were clumped using data from individuals of
European ancestry in 1000 Genomes Phase 3. IVW, MR-Egger, weighted-median and
weighted-mode analyses were conducted using the TwoSampleMR package v0.5.6.

The *APOE* gene is known to be associated with non-AD phenotypes such as cardiovascular disease⁹⁰ and type 2 diabetes (T2D)⁹¹. Both have been linked to depression in previous MR analyses^{92,93}. As such, the inclusion of *APOE* would violate MR's independence assumption. All MR analyses were therefore conducted excluding variants in the APOE region (chr19:45,020,859–45,844,508 (GRCh37)) as per Lord et al.⁹⁴.

523

2.11 Polygenic risk scores (PRS)

524 Polygenic risk scores (PRS) describe the sum of an individual's risk alleles, weighted by their effect size⁹⁵. The ten PHQ-9-MTAG, clinical depression and broad definition 525 depression GWAS were processed for PRS using the BayesR-SS function contained 526 527 within MegaPRS and implemented in LDAK v5.2.1.96. BayesR-SS assumes the BLD-528 LDAK heritability model, which incorporates 65 genome annotations pertaining to 529 genomic features such as whether the variants are in coding regions or highly obtained Annotation files were from 530 conserved⁹⁶. the LDAK website 531 (http://dougspeed.com/bldldak/). PRS calculation was restricted to the 1,217,311 532 HapMap3 SNPs, with strand ambiguous SNPs excluded.

PRS predictive utility for AD case/control status was assessed using logistic regression in three clinically ascertained AD cohorts: AddNeuroMed and Dementia Case Register Studies (ANM)⁹⁷ ($N_{cases} = 564$; $N_{controls} = 345$), the Alzheimer's Disease Neuroimaging Initiative (ADNI) (<u>https://adni.loni.usc.edu</u>) ($N_{cases} = 356$; $N_{controls} = 360$), and the Genetic and Environmental Risk in Alzheimer's Disease (GERAD1) Consortium

539 (https://portal.dementiasplatform.uk/CohortDirectory/Item?fingerPrintID=GERAD)

540 ($N_{cases} = 2,661$; $N_{controls} = 1,124$) (Supplementary Table 4). All analyses controlled for 541 age, sex, and 10 PCs, and were restricted to individuals aged ≥ 65 to provide clean 542 controls. As a sensitivity analysis, PRS were also calculated in these cohorts 543 excluding the *APOE* region. Genetic QC and imputation steps for these cohorts can 544 be viewed in detail in the study by Lord et al.⁹⁸.

- 545
- 546
- 547

548 3. RESULTS

549 3.1 PHQ-9 genome-wide meta-analyses

550 The MTAG meta-analyses identified a total of 40 genomic risk loci between the ten 551 PHQ-9 phenotypes (GWAS equivalent N range: 224,535 - 308,421). Only one depression symptom - suicidal thoughts - identified no genome-wide significant 552 variants. Three lead SNPs were shared with more than one PHQ-9 phenotype, leaving 553 a total of 37 unique genomic risk loci (Table 3). The significance of each of the lead 554 variants in each of the samples contributing to the meta-analysis can be seen in 555 Supplementary Table 5. eQTL mapping in FUMA mapped lead variants at genomic 556 risk loci to 76 genes (Supplementary Table 6). h_{SNP}^2 for the MTAG-PHQ-9 GWAS 557 ranged from 1.12% for suicidal thoughts to 6.78% for the PHQ-9 sum-score. $h_{SNP}^2 Z$ -558 scores were all > 4 (range: 6.59 - 18.50) (Supplementary Table 7), indicating 559 560 sufficient heritability to obtain reliable genetic correlation estimates in downstream 561 analyses⁵⁷. Genomic inflation factors (λ_{GC}) ranged from 1.0638 to 1.2156, with LDSC intercepts ranging from 0.9997 to 1.0007, indicating inflation was due to polygenic 562 563 signal as opposed to confounding due to population stratification^{56,99}. Manhattan and QQ plots can be viewed in Figure 2. 564

569 570

571

572

| Genomic Locus | CHR | Position | Lead Variant | Phenotype | p-value | BETA | SE | Effect Allele | MAF | Nearest Gene | eQTL Genes |
|------------------|-----|-----------|-----------------|----------------------------|----------------------|--------|-------|------------------|-------------|------------------|--|
| 1 | 1 | 21059837 | rs61778528 | Anhedonia | 1.27E-08 | -0.011 | 0.002 | Т | 0.384 | RP5-930J4.2 | KIF17, SH2D5, ECE1, HP1BP3, EIF4G3 |
| 2 | 1 | 51661974 | rs36116328 | Concentration Problems | 2.94E-08 | 0.011 | 0.002 | С | 0.052 | RP11-296A18.3 | EPS15, TTC39A, RNF11, CDKN2C, |
| 3 | 1 | 201787833 | rs2494112 | Sleep Problems | 4.46E-08 | 0.011 | 0.002 | А | 0.486 | NAV1:IPO9-AS1 | NAV1, LMOD1, SHISA4, RNPEP, |
| 4 | 1 | 201050212 | rcC1024204 | Fatigue | 3.81E-09 | -0.012 | 0.002 | G | 0.385 | SHISA4 | |
| 4 | 1 | 201859213 | 1561824384 | PHQ-9 Sum Score | 4.48E-11 | -0.014 | 0.002 | G | 0.385 | SHISA4 | NAVI, LIVIODI, SHISA4, IPO9, HIVIWII/A, RNPEF |
| 5 | 1 | 201919674 | rs2790898 | Feelings of Inadequacy | 2.54E-08 | 0.011 | 0.002 | Т | 0.425 | LMOD1 | LMOD1 , RNPEP, IPO9, SHISA4, TIMM17A |
| 6 | 2 | 66750564 | rs113851554 | Sleep Problems | 1.42E-14 | 0.016 | 0.002 | Т | 0.053 | MEIS1 | MEIS1 |
| 7 | 3 | 48812594 | rs116113836 | Depressed Mood | 2.74E-08 | 0.011 | 0.002 | А | 0.033 | PRKAR2A | AMT, ZNF589, ATRIP, NME6, WDR6, P4HTM, QRICH1, NICN1, RNF123, GMPPB, LAMB2, USP4, MST1, TREX1, TMA7, KLHDC8B |
| 8 | 3 | 117535095 | rs76917635 | Feelings of Inadequacy | 1.65E-08 | -0.012 | 0.002 | G | 0.194 | SAMP:RP11-384F7. | - |
| 9 | 3 | 117822025 | rs7619072 | Sleep Problems | 7.14E-11 | 0.013 | 0.002 | С | 0.229 | RP11-384F7.1 | LSAMP |
| 10 | 4 | 106217349 | rs2647239 | Sleep Problems | 1.17E-08 | -0.012 | 0.002 | G | 0.420 | RN7SL89P | PPA2, TET2 |
| 11 | 5 | 62392481 | rs181208594 | Psychomotor Changes | 2.72E-08 | 0.011 | 0.002 | G | 0.017 | RP11-586E1.1 | - |
| 12 | 6 | 28548674 | rs146918648 | Appetite Changes | 1.49E-08 | 0.012 | 0.002 | А | 0.027 | SCAND3 | ZSCAN9, PGBD1, ZKSCAN3, ZNF165, TRIM27, ZSCAN23, SCAND3, ZSCAN12, C6orf100" |
| 13 | 6 | 32555944 | rs35773267 | Fatigue | 1.63E-09 | 0.013 | 0.002 | Т | 0.372 | HLA-DRB1 | - |
| 14 | 7 | 12250378 | rs3807866 | Depressed Mood | 4.38E-08 | 0.011 | 0.002 | А | 0.398 | TMEM106B | TMEM106B |
| 15 | 7 | 12277442 | rs13234970 | Appetite Changes | 1.56E-08 | 0.012 | 0.002 | С | 0.400 | TMEM106B | - |
| 16 | 7 | 12285140 | rs12699338 | PHQ-9 Sum Score | 8.47E-09 | 0.012 | 0.002 | Т | 0.405 | TMEM106B | TMEM106B |
| 17 | 7 | 82394712 | rs763296 | Fatigue | 1.03E-10 | 0.013 | 0.002 | G | 0.495 | PCLO | - |
| 18 | 7 | 121955328 | rs3958046 | Appetite Changes | 3.58E-09 | 0.012 | 0.002 | Т | 0.389 | CADPS2 | - |
| 19 | 8 | 19551329 | rs13253689 | Fatigue | 4.55E-08 | -0.011 | 0.002 | С | 0.243 | CSGALNACT1 | INTS10, CSGALNACT1, LPL |
| 20 | 8 | 37211598 | rs150773120 | Appetite Changes | 1.19E-08 | 0.012 | 0.002 | А | 0.012 | RP11-527N22.1 | - |
| 21 | 8 | 73452488 | rs7824350 | Fatigue | 8.58E-09 | -0.012 | 0.002 | G | 0.410 | KCNB2 | - |
| 22 | 10 | 11149133 | rs61830447 | Inadequacy | 3.80E-08 | 0.011 | 0.002 | А | 0.243 | CELF2 | CELF2 |
| 23 | 12 | 57323523 | rs840161 | PHQ-9 Sum Score | 3.71E-09 | 0.012 | 0.002 | G | 0.339 | SDR9C7 | METTL21B, TMEM194A, STAT6, NAB2, RBMS2, LRP1 |
| 24 | 12 | 57331741 | rs725957 | Fatigue | 4.68E-08 | 0.011 | 0.002 | А | 0.394 | SDR9C7 | METTL21B, TMEM194A, STAT6, NAB2, RBMS2, LRP1, RDH16, DTX3, SDR9C7 |
| 25 | 12 | 109874794 | rs10850137 | Fatigue | 1.11E-09 | 0.013 | 0.002 | G | 0.336 | MYO1H | UBE3B, MMAB, ACACB, KCTD10, MVK, MYO1H FOXN4, UNG |
| | | | | Depressed Mood | 2.81E-08 | 0.011 | 0.002 | G | 0.103 | MIR4704 | |
| 26 | 13 | 66718798 | rs185907577 | Fatigue | 4.11E-09 | 0.012 | 0.002 | G | 0.103 | MIR4704 | - |
| | | | | PHQ-9 Sum Score | 9.73E-10 | 0.013 | 0.002 | G | 0.103 | MIR4704 | |
| 27 | 16 | 53801549 | rs9923147 | Appetite Changes | 1.74E-11 | 0.014 | 0.002 | Т | 0.443 | FTO | FTO |
| 28 | 17 | 56044110 | rs11654634 | PHQ-9 Sum Score | 8.48E-10 | 0.013 | 0.002 | С | 0.067 | VEZF1 | CUEDC1, TEX14 |
| 29 | 17 | 56124979 | rs11657437 | Anhedonia | 2.62E-08 | 0.011 | 0.002 | Α | 0.105 | RP11-159D12.10 | VEZF1 |
| 30 | 17 | 65989971 | rs113985803 | Appetite Changes | 4.18E-08 | -0.011 | 0.002 | Α | 0.226 | RP11-855A2.5 | BPTF, KPNA2, PSMD12 |
| 31 | 17 | 66045831 | rs74354868 | Fatigue | 2.78E-08 | 0.011 | 0.002 | Α | 0.229 | KPNA2 | BPTF, KPNA2, C17orf58, ARSG, PSMD12 |
| 32 | 18 | 35127427 | rs1557341 | PHQ-9 Sum Score | 1.94E-08 | -0.012 | 0.002 | С | 0.341 | CELF4 | - |
| 33 | 18 | 50754093 | rs62100775 | Fatigue PHQ-9 Sum Score | 1.92E-08 1.44E-08 | 0.012 | 0.002 | G G | 0.419 0.419 | DCC DCC | DCC |
| 34 | 18 | 50829023 | rs11877505 | Anhedonia | 3.40E-09 | 0.012 | 0.002 | G | 0.388 | DCC | DCC |
| 35 | 18 | 53415377 | rs4800995 | Fatigue | 4.60E-10 | 0.013 | 0.002 | А | 0.214 | RP11-397A16.1 | - |
| 36 | 18 | 71620555 | rs75020204 | Sleep Problems | 4.34E-08 | -0.011 | 0.002 | С | 0.071 | RP11-25L3.3 | - |
| 37 | 19 | 7871720 | rs3223231 | Anhedonia | 4.40E-09 | -0.012 | 0.002 | А | 0.462 | EXOSC3P2 | - |
| 573 | | | • | | | | | | | | |

574

575 Table 3: Genomic risk loci from the 10 MTAG-PHQ-9 genome-wide association meta-analyses. Nearest gene is

576 based on positional mapping and ANNOVAR annotation. Expression quantitative trait loci (eQTL) mapping was

577 *limited to* $p_{FDR} \le 0.05$ *in the selected eQTL datasets (see: Methods). Specific tissues with significant* p_{FDR} *can be*

578 seen in Supplementary Table 2.



Figure 2: Manhattan and QQ-plots for each of the 10 MTAG-PHQ-9 GWAS meta-analyses. The red lines on the Manhattan plots indicate genome-wide significance ($p \le 5 \times 10^8$), while the blue lines indicates suggestive significance ($p \le 1e-5$). Top variants at each genomic risk loci are annotated.

583

584

585

3.2 Genetic correlations

Of the 72 bivariate genetic correlations calculated between the 12 depression 586 phenotypes and the six AD GWAS, 24 were nominally significant and 20 remained 587 significant at $p_{\text{FDR}} \le 0.05$ (r_q range: -0.25 – 0.35; p-value range: 1.25 x 10⁻² – 4.01 x 10⁻² 588 ⁵; p_{FDR} range: 4.5 x 10⁻² – 1.9 x 10⁻³). Of these, 19 were identified when the AD GWAS 589 590 in the pair contained either clinical+proxy cases and controls, or proxy-only cases 591 and controls (Figure 3; Supplementary Table 8). Only one *p*_{FDR} significant association was found when using a clinical AD GWAS - between suicidal thoughts and 592 Wightman et al. ($r_q = -0.25$, p = 6.78 x 10⁻³, p-value = 6.78 x 10⁻³; p_{EDR} = 3.48 x 10⁻²). 593 All depression phenotypes were significantly genetically correlated with each other 594 595 $(r_q \text{ range: } 0.57 - 0.98; p \text{-values} \le 3.71 \times 10^{-23})$ (Supplementary Table 9, Supplementary Material 1). Only one PHQ-9 symptom pair - concentration problems and 596 psychomotor changes - showed a genetic correlation that was not statistically 597 598 different from one (95% CI included one), indicating genetic heterogeneity across depression symptoms. 599

600

601

602

603

604

605

606

607

| | | Anted | Inite Appeti | e Changes | htation Proble | ns sed Mood | Feeling | psych | ol motor Change Sleaf | noblems Suicide | PHQ9 | Sun Score | Oppession (H | Depless | A. LEON A. LEO |
|-----------------------|-----------------------------------|---------------------|--------------|----------------------|----------------|----------------|---------|----------------------|-----------------------------|--------------------|--------------------|-----------|--------------|---------|--|
| ſ | - Bellenguez et al. (2022) | - <mark>0.02</mark> | -0.07 | - <mark>0.0</mark> 1 | 0.03 | -0.04 | 0 | - <mark>0.0</mark> 2 | 0 | -0.06 | <mark>-0.02</mark> | -0.01 | -0.04 | | - 0.8 |
| Clinical + - Proxy | Wightman et al. (2021) | 0.1 | 0.07 | 0.2 | 0.15 | 0.12 | 0.12 | 0.09 | 0.19 | 0.02 | 0.15 | 0.1 | 0.09 | - 0. | - 0.6 |
| | Jansen et al. (2019) | 0.26 | 0.22 | 0.27 | 0.28 | 0.25 | 0.22 | 0.31 | 0.35 | 0.18 | 0.31 | 0.24 | 0.22 | - | - 0.2 |
| Proxy-only | - Marioni et al. (2018) - | 0.04 | 0.1 | 0.13 | 0.16 | 0.15 | 0.17 | 0.09 | 0.19 | 0.18 | 0.16 | 0.1 | 0.01 | | 0.2 |
| Clinical- | - Wightman et al. (no UKB) (2021) | 0 | -0.13 | 0.06 | 0.01 | -0.02 | -0.01 | 0.09 | -0.05 | -0.25 | -0.04 | 0 | 0.11 | - | 0.4 |
| oniy | Kunkle et al. (2019) | 0.05 | -0.05 | 0.07 | 0.06 | 0 | 0.02 | 0.08 | -0.07 | -0.11 | 0 | -0.04 | 0.07 | | 0.8 |

608

609Figure 3: Heatmap of High Definition Likelihood (HDL) calculated genetic correlations between610depression items and the six Alzheimer's disease genome-wide association studies of varying611proxy/clinical case/control ascertainment. The colour of each square indicates the strength of the612correlation on a scale of -1 to 1. Fill size of the square indicates uncorrected p-value significance.613Genetic correlations significant at $p_{FDR} \leq 0.05$ are circled.

- 614
- 615

616

3.3 Local genetic correlations

617 After univariate testing, a total of 4271 bivariate local genetic correlation tests were conducted across 324 genomic loci. Of these tests, 716 were nominally significant 618 and 15 remained significant at $p_{\text{FDR}} \leq 0.05$ across 14 unique genomic loci (local r_a 619 range: -0.81 - 0.82; *p*-value range: $1.48 \times 10^{-4} - 4.2 \times 10^{-6}$; *p*_{FDR} range = $4.22 \times 10^{-2} - 4.2 \times 10^{-2}$ 620 1.38 x 10⁻²) (Supplementary Table 10). Of the 15 statistically significant tests, ten were 621 622 identified when using clinical+proxy/proxy-only AD GWAS. No depression phenotype showed a statistically significant association at the same genomic locus with more 623 than one AD GWAS. However, for ten of the 15 statistically significant tests, nominally 624 625 significant local genetic correlation was observed between the depression 626 phenotype and at least one additional AD GWAS at the same loci (Supplementary **Table 11**). Only locus 1790 (chr12:51769420– 53039987) showed p_{EDR} significant 627 local genetic correlation with more than one depression phenotype - concentration 628 problems and sleep problems, both with the clinical-only Wightman et al. GWAS. The 629 630 number of positively and negatively correlated loci identified between each phenotype pair can be viewed in Supplementary Table 12. 631

632

633 **3.4 Colocalisation**

Following LAVA, 14 p_{FDR} significant regions of local genetic correlation were passed 634 to the COLOC-reporter pipeline across 15 depression-AD phenotype pairs. A further 635 14 colocalisation tests were conducted where nominally significant local genetic 636 correlation was observed at a p_{FDR} significant loci between the same depression 637 phenotype and a different AD GWAS. As such, a total of 29 statistical colocalisation 638 639 tests were conducted to follow up LAVA results. No 95% credible sets were identified by SuSiE for any phenotype pairs in these regions. As such, all analyses were 640 conducted under the single causal variant assumption of *coloc.abf*. There was no 641 642 evidence of colocalisation in any of these loci (mean PP.H₄ = 0.59%) (Supplementary Table 11). All but two of these tests indicated no causal variant present in either 643 644 phenotype (PP.H₀ > 0.8). The two tests in locus 319 (chr2:126754028-127895644), indicated strong probability of a causal variant for the Kunkle et al.¹⁴ and Wightman 645 et al.⁴⁵ clinical AD GWAS (PP.H₂ > 0.9) . This locus contains *BIN1*, a known risk gene 646 for AD involved in tau regulation^{100,101}. 647

An additional 762 colocalisation tests were conducted with the six AD GWAS 648 649 using regions +/-250kb ($r^2 > 0.1$) lead variants from the MTAG-PHQ-9, broad and 650 clinical depression GWAS. SuSiE identified evidence of colocalisation in regions +/-651 250kb of lead variants at genomic risk loci 14 (depressed mood), 15 (appetite change), 16 (PHQ-9 sum score) and for broad depression at chr7:12000402-652 12500402 (PP.H₄ range: 0.79 – 0.85), all with the same three AD GWAS – Bellenguez 653 et al.¹⁷, Wightman et al.¹⁶, and Wightman et al. (excluding the UKB)⁴⁵ (Supplementary 654
 Table 13). These colocalisations were all in the region of the transmembrane protein
 655 106B gene (TMEM106B) - visualised using LocusZoom¹⁰² in Figure 4. Colocalisation 656 was also identified for the same phenotype pairs at the same loci under the single 657 causal variant assumption of *coloc.abf* (Supplementary Table 14). The same 658 659 depression phenotypes and loci were suggestive of colocalisation with Jansen et al.¹⁵ (PP.H₄ > 0.6). In a follow-up analysis, we assessed statistical colocalisation +/-250kb 660 661 TMEM106B (chr7:12000920-12532993) between these four AD GWAS and all remaining depression phenotypes. Additional evidence of colocalisation was 662 identified at *TMEM106B* between fatigue and the Bellenguez et al.¹⁷, Wightman et 663 al.¹⁶, and Wightman et al. (excluding the UKB)⁴⁵ AD GWAS (Supplementary Table 15), 664 and was suggestive for Jansen et al.¹⁵ (Supplementary Table 16). Evidence of 665 colocalisation was also suggestive for psychomotor changes with Bellenguez et al.¹⁷. 666 Wightman et al.¹⁶, and Wightman et al. (excluding the UKB)⁴⁵ (PP.H₄ > 0.6). 667

668 669

670



671Figure 4: LocusZoom plots of the transmembrane protein 106B (TMEM106B) gene region containing672evidence of colocalisation (PP.H_4 \leq 0.8). for (A.) broad depression, (B.) appetite changes, (C.)673depressed mood, (D.), the PHQ-9 sum score, (E.) Bellenguez et al., (F.) Wightman et al. and (G.)674Wightman et al. excluding the UK Biobank. The most significant variant for each phenotype is labelled675in their respective plot.

676 677

678 **3.5 Mendelian Randomisation**

We conducted 144 MR tests between the depression phenotypes and AD – 72 in
each direction. In CAUSE, no significant causal association was identified between
any of the depression items and AD in either direction even at nominal significance
(Supplementary Table 17).

F-statistics indicated that instrument strength was sufficient (F_{Mean} range: 22.43 683 - 63.36; F_{Min} range: 20.84 - 31.56; F_{Max} range: 26.37 - 402.86), as did I² for instrument 684 suitability for MR-Egger (I² range: 0.91 – 0.98). A $p_{FDR} \leq 0.05$ was applied in each of 685 the other MR methods to correct for the 144 tests conducted, after which no 686 statistically significant associations were observed in any method. Three nominally 687 significant causal associations where a depression item was the exposure (β range 688 = 0.21 - 1.59; *p*-value range = 0.01 - 2e-3) and two where an AD GWAS was the 689 690 exposure (β range = 0.018 - 0.02; p-value range = 0.01 - 0.02) were detected by

IVW-MR, of which three we nominally significant in weighted-median MR. No 691 692 significant pleiotropy (MR-Egger intercept test p-value ≤ 0.05) or heterogeneity (IVW) Cochran's Q p-value ≤ 0.05) was detected for these five tests. However, nominally 693 694 significant estimates were only observed between exposures and outcomes where the AD GWAS contained proxy+clinical or proxy-only cases/controls and where the 695 GWAS used for both exposure and outcome were either majority or entirety derived 696 697 from the UK Biobank, suggesting sample overlap as a potential source of bias. MR-698 PRESSO detected and excluded significant outliers in 42 tests, returning outlier-699 corrected causal estimates. Results remained non-significant. Full MR results can be 700 viewed in Supplementary Table 18.

701

3.6 Polygenic risk scores (PRS)

No statistically significant associations were detected between any of the depression phenotype PRS and AD case/control status in any of the three AD target samples $(p_{FDR} \le 0.05, \text{ corrected within each sample}), with only the suicidal thoughts PRS$ negatively nominally associated with AD case/control in the ADNI cohort $(Nagelkerke's pseudo-r2 = 0.01, OR [95% CI] = 0.83 [0.72–0.94], <math>\beta$ = -0.19, SE = 0.07, *p*-value = 7.90 x 10⁻³). Exclusion of the APOE region had no effect on results (Supplementary Table 19, Supplementary Material 2).

709 710

4. Discussion

In this study, we performed the first and largest genome-wide meta-analysis of PHQ-711 712 9 depression symptom items to date (GWAS equivalent Nrange: 224,535 – 308,421), 713 identifying 37 genomic risk loci. Follow-up analyses examining the genetic overlap 714 between depression/depression symptoms and AD identified 20 significant global 715 correlations and 15 significant local correlations at 14 loci across six AD GWAS with 716 varying proportion of clinical case/control ascertainment. Significant global genetic 717 correlation were primarily with AD GWAS containing proxy cases and controls. No colocalisation was identified at any of the regions of local genetic correlation. 718 719 However, there was strong evidence of colocalisation between depression several 720 phenotypes and AD in the region of *TMEM106B*. Overall, MR did not suggest that 721 depression or its symptoms were causal for AD, nor vice versa, while polygenic risk 722 scores for depression phenotypes were not predictive of AD case/control status in 723 three clinical AD samples.

The increased power of our PHQ-9 GWAS allowed for the identification of 28 more genomic risk loci than the previous analysis by Thorp et al.²⁹. Several of the loci identified in this study have shown previous associations with related phenotypes. For example, *SHISA4* – here identified in association with fatigue symptoms – has been previously implicated as playing a role in disrupted sleep¹⁰³ and daytime

napping¹⁰⁴. The top variant for sleep problems at genomic risk loci 6 (MEIS1) -729 rs113851554 (chr2: 66750564) - was also the top variant in a previous GWAS of 730 insomnia and restless leg syndrome¹⁰⁵. Additionally, the obesity gene *FTO*¹⁰⁶ was 731 732 identified as a genomic risk loci for appetite changes. Although the role of FTO in depression is inconclusive¹⁰⁷, it has been recently linked to anxiety and depression 733 734 symptoms in individuals with anorexia nervosa (AN)¹⁰⁸. Consequently, its 735 identification in association with appetite change symptoms – a phenotype relevant 736 to eating behaviours - suggests that symptom-based genetic analysis can help 737 identify the phenotype-relevant biology of individual depression symptoms. Taken 738 alongside the fact that only three of the genomic risk loci were shared between more than one depression symptom phenotype, our GWAS meta-analysis backs findings 739 740 by Thorp et al.²⁹ of genetic heterogeneity between depression symptoms.

741 Our findings also highlight genetic similarities between depression symptoms. 742 For example, *TMEM106B* – a gene identified in previous depression GWAS^{11,12} – was 743 the nearest gene to lead variants for three PHQ-9 items - appetite changes (rs13234970), depressed mood (rs3807866) and the PHQ-9 sum score 744 (rs12699338). TMEM106B was strongly suggested as a causal gene in a recent multi-745 ancestry depression GWAS¹⁰⁹. Further, dysregulation of *TMEM106B* expression has 746 been implicated in association with MDD¹¹⁰ and with anxious and weight gain MDD 747 subtypes – both associated with treatment resistance¹¹¹. *TMEM106B* has also been 748 implicated in self-reported diagnosis of anxiety disorder¹¹², neuroticism¹¹³ and in a 749 latent factor GWAS of depressive, manic and psychotic symptoms/disorders¹¹⁴, 750 suggesting it is linked to psychiatric risk more generally. 751

752 That colocalisation is observed in the *TMEM106B* region between multiple depression phenotypes and both proxy+clinical and clinical-only AD is therefore of 753 particular interest. TMEM106B plays a role in lysosomal function - particularly in 754 755 motor neurons¹¹⁵ – and is classically considered a risk gene for frontotemporal dementia¹¹⁶. It is has also been identified in recent AD GWAS^{16,17}, and is associated 756 757 with brain aging, cognitive decline, and neurodegeneration across other brain 758 disorders including Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson's 759 Disease¹¹⁷⁻¹²². Further, *TMEM106B* has been linked to higher CSF levels of neurofilament light (NfL)¹²³ – itself predictive of cognitive decline, brain atrophy and 760 cortical amyloid burden in individuals with AD and Mild Cognitive Impairment 761 762 (MCI)¹²⁴. A recent study also identified higher levels of plasma NfL in individuals with depression, although the sample size of this study was relatively small¹²⁵. Thus, 763 colocalisation between depression phenotypes and AD at *TMEM106B* indicates that 764 765 depression may itself be genetically linked to overall brain health and resulting general dementia risk. Two previous studies have identified *TMEM106B* as playing a 766 role in both depression and AD^{20,21}. However, our study suggests that this overlap 767

768 may be driven by the genetic architecture of specific depression symptoms,769 highlighting the benefits of symptom-level genetic analysis.

770 A mixed picture is painted across our other downstream analyses. Depression/depression symptom PRS were not predictive of AD case/control status 771 in three clinical samples. Additionally, we do not find evidence of any causal 772 773 associations using MR. These MR findings are in line with a number of previous 774 studies^{19,39}, but in contradiction to that conducted by Harerimana et al.²². In this study, 775 we do not recapitulate the causal association identified by Harerimana et al.²² for broad depression on AD as measured by Jansen et al.¹⁵ – even at a nominal level. 776 This is possibly due to the exclusion of rare variants (MAF < 0.01), and as such future 777 investigation into the role of rare variants in shared risk for depression and AD is 778 779 warranted. However, the lack of evidence in these analyses versus the observed 780 relationship in epidemiological studies suggests the presence of unidentified 781 confounding. The investigation of possible confounding is an important step for future 782 research to help us better understanded the association between depression and 783 dementia.

784 While previous studies have shown that the direction of effect in MR can change depending on whether the outcome AD GWAS contains proxy or clinical 785 cases/controls^{38,39}, this study is - to the best of our knowledge - the first to 786 demonstrate a similar effect with genetic correlations. Of the significant genetic 787 correlations we identified, 95% were identified in proxy+clinical or proxy-only AD 788 GWAS. Where two previous studies^{20,22} identified a genetic correlation between 789 depression and AD, it is noticeable that they used the Jansen et al. proxy+clinial AD 790 791 GWAS as their primary outcome. Further, in the study by Harerimana et al.²² sensitivity analysis did not observe a significant genetic correlation using the clinical-792 only GWAS by Kunkle et al.¹⁴. 793

794 Exactly why depression/depression symptoms show differences in genetic 795 correlation between proxy and clinical AD is a matter of interest. It is noted that most 796 individuals with dementia are cared for by a family member while they are still living in the community¹²⁶. Caregivers incur considerable lifestyle changes, emotional 797 798 stress, and social strain^{127,128} and depression is reported in up to 50% of caregivers 799 for individuals with dementia¹²⁹. As such, the genetic correlations between depression/depression symptoms and proxy-AD may result from increased 800 801 depression risk due to caregiver responsibilities, exacerbated by a genetic risk. However, this would not explain why no genetic correlations were identified with the 802 Bellenguez et al.¹⁷ GWAS despite this study also containing proxy+clinical 803 phenotyping. As mentioned, Bellenguez et al.¹⁷ define proxy cases/controls as a 804 binary phenotype, whereas Wightman et al.¹⁶ and Jansen et al.¹⁵ define proxy 805 806 cases/controls as a continuous phenotype. These phenotyping differences likely

partially explain the differences in the genetic correlation results, given that these AD 807 GWAS all use the same data from the UK Biobank. However, the proxy-only Marioni 808 et al.³⁷ GWAS – with which genetic correlations were also observed – is a meta-809 810 analysis of maternal and paternal AD GWAS where parental age-at-diagnosis/ageof-death is controlled for in the GWAS model, instead of being used for weighting the 811 proxy phenotype prior analysis. Taking this into account, and considering that 812 depression is itself associated with all-cause mortality¹³⁰, it is possible that including 813 814 age-at-diagnosis/age-of-death in proxy-AD phenotyping induces a form of bias in 815 later cross-trait analyses when the other trait is itself associated with longevity. Further 816 investigation of this issue is required.

Nonetheless, conflicting results such as these pose a problem to researchers 817 818 seeking to identify genetic relationships between AD and its risk factors. Large 819 differences in the presence or direction of effects depending on which AD GWAS is 820 used to assess associations increases the difficulty in discerning true associations 821 for the purpose of designing interventions. As such, we suggest that future genetic 822 studies examining genetic overlap between AD risk factors and AD conduct primary 823 analyses using a clinically ascertained AD phenotype. A range of AD GWAS with different proxy/clinical ascertainment could then be used to examine the consistency 824 825 of results in relation to clinical AD. While this approach would limit researchers to AD GWAS with slightly smaller sample sizes for primary analyses, it would also ensure 826 that results are driven not by AD proxy phenotyping alone. 827

828 This study has several limitations. Despite being the largest meta-analysis of 829 PHQ-9 items to date, the ability to detect genome-wide significant variants was likely 830 limited by small sample sizes relative to other psychiatric conditions. This includes 831 depression itself, where sample sizes have exceeded one million¹³. Larger samples 832 are required for future studies if we are to truly elucidate the unique genetic 833 architecture of individual depression symptoms. Additionally, our analyses were restricted to individuals of European ancestry. GWAS results may therefore have poor 834 835 transferability to other ancestry groups. Although efforts are underway to address the issue of lack of diversity in human genetic studies, urgency is required so that studies 836 can be conducted across ancestry groups using equivalent sample sizes. Our study 837 makes also heavy use of data from the UKB. The UKB is known to be affected by 838 839 healthy volunteer bias, and as a consequence is not fully representative of the wider 840 population¹³¹.

841 It is worth noting that this study focused on depression as a risk factor for AD. 842 However, there is evidence that some forms of later life depression are in fact a 843 prodromal phase of dementia onset^{8,132}, and may be related to levels of dementia 844 biomarkers such as plasma A β 42 and CSF p-tau¹³³. As such, dementia-related 845 depression may be biologically distinct from depression as a mental health disorder. While sufficient sample sizes are likely difficult to obtain, future large scale genomic
studies of dementia-related depression – as has been undertaken with psychosis in
AD¹³⁴ – would prove illuminating on this matter.

849 In conclusion, this study describes the largest genome-wide meta-analysis of PHQ-9 depression symptom items to date (GWAS equivalent N range: 224,535 -850 308,421), identifying 37 unique genomic risk loci. Genetic correlations between 851 852 depression/depression symptoms and AD were primarily observed when the AD GWAS contained clinical+proxy or proxy-only AD case/control ascertainment. 853 854 Further, this study does not support depression or its symptoms as being causal for AD. However, colocalisation in the *TMEM106B* region between four depression 855 phenotypes and AD across both proxy and clinical AD GWAS suggests future 856 857 research into the shared biological mechanisms underlying the role of this locus in 858 depression and AD are warranted.

859

860861 5. Funding and Acknowledgements

LG is funded by the King's College London DRIVE-Health Centre for Doctoral Training
and the Perron Institute for Neurological and Translational. PP is funded by
Alzheimer's Research UK. SK is funded by MSWA and the Perron Institute. HLD
acknowledges funding from the Economic and Social Research Council (ESRC).
DMH is supported by a Sir Henry Wellcome Postdoctoral Fellowship (Reference
213674/Z/18/Z).

869

This paper represents independent research part-funded by the NIHR Maudsley
Biomedical Research Centre at South London and Maudsley NHS Foundation Trust
and King's College London. The views expressed are those of the author(s) and not
necessarily those of the NIHR or the Department of Health and Social Care.

874

This research has been conducted using the UK Biobank Resource under
Application Number 18177. We thank the UK Biobank Team for collecting the data
and making it available. We also thank the UK Biobank participants.

878

We thank the GLAD Study volunteers for their participation, and gratefully 879 880 acknowledge the NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health Research, NHS Blood and 881 Transplant, and Health Data Research UK as part of the Digital Innovation Hub 882 Programme. This study presents independent research funded by the NIHR 883 Biomedical Research Centre at South London and Maudsley NHS Foundation Trust 884 King's 885 and College London. Further information can be found at

- http://brc.slam.nhs.uk/about/core-facilities/bioresource. The views expressed are
 those of the authors and not necessarily those of the NHS, the NIHR, the HSC R&D
 Division, King's College London, or the Department of Health and Social Care.
- 889

The PROTECT study was funded/supported by the National Institute of Health and
Care Research Exeter Biomedical Research Centre. PROTECT genetic data was
funded in part by the University of Exeter through the MRC Proximity to Discovery:
Industry Engagement Fund (External Collaboration, Innovation and Entrepreneurism:
Translational Medicine in Exeter 2 (EXCITEME2) ref. MC_PC_17189). Genotyping was
performed at deCODE Genetics. The views expressed are those of the author(s) and
not necessarily those of the NIHR or the Dept of Health and Social Care.

897

As data used in this study was obtained from the ADNI database, the ADNI investigators contributed to the conception of the sample and acquisition of this data, although were not participants in other parts of this study, such as conceptualisation, data analysis or writing. A full acknowledgment list of ADNI investigators can be found at: <u>https://adni.loni.usc.edu/wp-</u>

- 903 content/uploads/how to apply/ADNI Acknowledgement List.pdf
- 904

905 Similarly, data was obtained from the GERAD1 Consortium and GERAD1
906 investigators contributed to the conception of the cohort and acquisition of this data,
907 but did not participate in the conceptualisation, analysis or writing of this study. A full
908 list of GERAD1 collaborators can be found in Supplementary Material 3.

909

We also thank and acknowledge the contribution and use of the CREATE highperformance computing cluster at King's College London (King's College London.
(2022). King's Computational Research, Engineering and Technology Environment
(CREATE). Retrieved May 23, 2023, from https://doi.org/10.18742/rnvf-m076).

914

915 The analysis flowchart in Figure 1. was created and licenced with BioRender 916 (www.biorender.com)

917

918 6. Conflicts of Interest

- 919 CML is on the Scientific Advisory Board of Myriad Neuroscience and has received920 honoraria for consultancy from UCB.
- 921

922 7. Data availability

923 All GWAS summary statistics generated in the process of conducting this study will924 be deposited in the NHGRI-EBI Catalog of human genome-wide association studies

| 925 | (GWAS Cata | alog) following | peer-review and p | ublication. This study was | pre-registered |
|-------------------|------------------------|--------------------------|----------------------|----------------------------|----------------|
| 926 | on | the | Open | Science | Framework |
| 927 | (<u>https://osf.i</u> | <u>o/94q35/?view</u> | _only=e77f72d41(| 00d47eea7f3ef07dfa9c05 | <u>)</u>). |
| 928 929 930 | This study n | nade use of pu | iblicly available ar | nalysis software: | |
| 931 | MungeSum | stats | | | |
| 932 | (https://neur | rogenomics.git | hub.io/MungeSum | nstats/articles/MungeSums | stats.html) |
| 933 | | | · | | , |
| 934 | REGENIE (| https://rgcgithu | b.github.io/regeni | <u>e/)</u> | |
| 935 | | | | | |
| 936 | MTAG (<u>http</u> | s://github.com/ | JonJala/mtag) | | |
| 937 | | | | | |
| 938 | METAL (<u>htt</u> | os://genome.sp | h.umich.edu/wiki/ | METAL_Documentation) | |
| 939 | | | | | |
| 940 | FUMA GWA | S (<u>https://fuma</u> | a.ctglab.nl) | | |
| 941 | | | | | |
| 942 | LDSC (<u>https</u> | s://github.com/ | <u>bulik/ldsc</u>) | | |
| 943 | | | | | |
| 944 | HDL (<u>https:/</u> | //github.com/zł | <u>nenin/HDL)</u> | | |
| 945 | | | | | |
| 946 | LAVA (<u>https</u> | ://github.com/j | osefin-werme/LAV | <u>/A</u>) | |
| 947 | | | | | |
| 948 | susieR (<u>http</u> | s://stephenslal | o.github.io/susieR | <u>/index.html</u>) | |
| 949 | | | | | |
| 950 | coloc (<u>https</u> | ://chr1swallace | e.github.io/coloc/) | | |
| 951 | | | | | |
| 952 | COLOC-rep | orter (<u>https://g</u> | ithub.com/Thomas | sPSpargo/COLOC-reporte | <u>er</u>) |
| 953 | | | | | |
| 954 | CAUSE (<u>htt</u> | <u>os://jean997.gi</u> | thub.io/cause/inde | <u>ex.html</u>) | |
| 955 | | | | | |
| 956 | TwoSample | MR (<u>https://mro</u> | cieu.github.io/Two | <u>SampleMR/</u>) | |
| 957 | | | | A. | |
| 958 | MegaPRS (| <u>nttps://dougspe</u> | eed.com/megaprs | <u>6</u> () | |
| 959 | | | | | |

960 References

- 961
- 962 1. Byers, A.L., and Yaffe, K. (2011). Depression and risk of developing dementia. Nat. Rev.
 963 Neurol. 7, 323–331.
- 2. Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne,
- 965 C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020). Dementia prevention,
- 966 intervention, and care: 2020 report of the Lancet Commission. Lancet 396, 413–446.
- 967 3. Yu, O.-C., Jung, B., Go, H., Park, M., and Ha, I.-H. (2020). Association between dementia
- and depression: a retrospective study using the Korean National Health Insurance Service-
- 969 National Sample Cohort database. BMJ Open 10, e034924.
- 970 4. Yang, W., Li, X., Pan, K.-Y., Yang, R., Song, R., Qi, X., Pedersen, N.L., and Xu, W.
- 971 (2021). Association of life-course depression with the risk of dementia in late life: A
- nationwide twin study. Alzheimers Dement. 17, 1383–1390.
- 973 5. Richmond-Rakerd, L.S., D'Souza, S., Milne, B.J., Caspi, A., and Moffitt, T.E. (2022).
- 974 Longitudinal Associations of Mental Disorders With Dementia: 30-Year Analysis of 1.7
- 975 Million New Zealand Citizens. JAMA Psychiatry 79, 333–340.
- 976 6. Yang, L., Deng, Y.-T., Leng, Y., Ou, Y.-N., Li, Y.-Z., Chen, S.-D., He, X.-Y., Wu, B.-S.,
- 977 Huang, S.-Y., Zhang, Y.-R., et al. (2022). Depression, depression treatments, and risk of
- 978 incident dementia: A prospective cohort study of 354,313 participants. Biol. Psychiatry.
- 979 7. GBD 2016 Dementia Collaborators (2019). Global, regional, and national burden of
- Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global
 Burden of Disease Study 2016. Lancet Neurol. *18*, 88–106.
- 8. Dafsari, F.S., and Jessen, F. (2020). Depression-an underrecognized target for prevention
 of dementia in Alzheimer's disease. Transl. Psychiatry 10, 160.
- 984 9. Corfield, E.C., Yang, Y., Martin, N.G., and Nyholt, D.R. (2017). A continuum of genetic
 985 liability for minor and major depression. Transl. Psychiatry 7, e1131.
- 986 10. Gatz, M., Reynolds, C.A., Fratiglioni, L., Johansson, B., Mortimer, J.A., Berg, S., Fiske,
- A., and Pedersen, N.L. (2006). Role of genes and environments for explaining Alzheimer
 disease. Arch. Gen. Psychiatry 63, 168–174.
- 989 11. Wray, N.R., Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E.M., Abdellaoui, A.,
- Adams, M.J., Agerbo, E., Air, T.M., Andlauer, T.M.F., et al. (2018). Genome-wide
- association analyses identify 44 risk variants and refine the genetic architecture of majordepression. Nat. Genet. 50, 668–681.
- 993 12. Howard, D.M., Adams, M.J., Clarke, T.-K., Hafferty, J.D., Gibson, J., Shirali, M.,
- 994 Coleman, J.R.I., Hagenaars, S.P., Ward, J., Wigmore, E.M., et al. (2019). Genome-wide
- 995 meta-analysis of depression identifies 102 independent variants and highlights the importance
- 996 of the prefrontal brain regions. Nat. Neurosci. 22, 343–352.
- 997 13. Levey, D.F., Stein, M.B., Wendt, F.R., Pathak, G.A., Zhou, H., Aslan, M., Quaden, R.,
- 998 Harrington, K.M., Nuñez, Y.Z., Overstreet, C., et al. (2021). Bi-ancestral depression GWAS
- 999 in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new
- 1000 therapeutic directions. Nat. Neurosci. 24, 954–963.
- 1001 14. Kunkle, B.W., Grenier-Boley, B., Sims, R., Bis, J.C., Damotte, V., Naj, A.C., Boland, A.,
- 1002 Vronskaya, M., van der Lee, S.J., Amlie-Wolf, A., et al. (2019). Genetic meta-analysis of
- 1003 diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and 1004 lipid processing. Nat. Genet. 51, 414–430.
- 1005 15. Jansen, I.E., Savage, J.E., Watanabe, K., Bryois, J., Williams, D.M., Steinberg, S.,
- 1006 Sealock, J., Karlsson, I.K., Hägg, S., Athanasiu, L., et al. (2019). Genome-wide meta-analysis
- identifies new loci and functional pathways influencing Alzheimer's disease risk. Nat. Genet.
 51, 404–413.
- 1009 16. Wightman, D.P., Jansen, I.E., Savage, J.E., Shadrin, A.A., Bahrami, S., Holland, D.,

- 1010 Rongve, A., Børte, S., Winsvold, B.S., Drange, O.K., et al. (2021). A genome-wide
- association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease.
 Nat. Genet. 53, 1276–1282.
- 1013 17. Bellenguez, C., Küçükali, F., Jansen, I.E., Kleineidam, L., Moreno-Grau, S., Amin, N.,
- 1014 Naj, A.C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022). New insights
- 1015 into the genetic etiology of Alzheimer's disease and related dementias. Nat. Genet. 54, 412–
- 1016 436.
- 1017 18. Gibson, J., Russ, T.C., Adams, M.J., Clarke, T.K., Howard, D.M., Hall, L.S., Fernandez-
- 1018 Pujals, A.M., Wigmore, E.M., Hayward, C., Davies, G., et al. (2017). Assessing the presence
- 1019 of shared genetic architecture between Alzheimer's disease and major depressive disorder
- using genome-wide association data. Transl. Psychiatry 7, e1094.
- 1021 19. Andrews, S.J., Fulton-Howard, B., O'Reilly, P., Marcora, E., Goate, A.M., and
- 1022 collaborators of the Alzheimer's Disease Genetics Consortium (2021). Causal associations
- between modifiable risk factors and the alzheimer's phenome. Ann. Neurol. *89*, 54–65.
- 1024 20. Santos, F.C.D., Mendes-Silva, A.P., Nikolova, Y.C., Sibille, E., and Diniz, B.S. (2021).
- 1025 Genetic overlap between major depression, bipolar disorder and Alzheimer's Disease.1026 MedRxiv.
- 1027 21. Monereo-Sánchez, J., Schram, M.T., Frei, O., O'Connell, K., Shadrin, A.A., Smeland,
- 1028 O.B., Westlye, L.T., Andreassen, O.A., Kaufmann, T., Linden, D.E.J., et al. (2021). Genetic
- 1029 overlap between alzheimer's disease and depression mapped onto the brain. Front. Neurosci.1030 15, 653130.
- 1031 22. Harerimana, N.V., Liu, Y., Gerasimov, E.S., Duong, D., Beach, T.G., Reiman, E.M.,
- Schneider, J.A., Boyle, P., Lori, A., Bennett, D.A., et al. (2022). Genetic evidence supporting
 a causal role of depression in alzheimer's disease. Biol. Psychiatry 92, 25–33.
- 1034 23. American Psychiatric Association (2013). Depressive Disorders. In Diagnostic and
- 1035 Statistical Manual of Mental Disorders, (American Psychiatric Association), p.
- 1036 24. Fried, E.I., and Nesse, R.M. (2015). Depression is not a consistent syndrome: An
- investigation of unique symptom patterns in the STAR*D study. J. Affect. Disord. 172, 96–
 102.
- 25. Zimmerman, M., Ellison, W., Young, D., Chelminski, I., and Dalrymple, K. (2015). How
 many different ways do patients meet the diagnostic criteria for major depressive disorder?
 Compr. Psychiatry 56, 29–34.
- 1042 26. Park, S.-C., Kim, J.-M., Jun, T.-Y., Lee, M.-S., Kim, J.-B., Yim, H.-W., and Park, Y.C.
- 1043 (2017). How many different symptom combinations fulfil the diagnostic criteria for major
- 1044 depressive disorder? Results from the CRESCEND study. Nord J Psychiatry 71, 217–222.
- 1045 27. Cai, N., Choi, K.W., and Fried, E.I. (2020). Reviewing the genetics of heterogeneity in
- depression: operationalizations, manifestations and etiologies. Hum. Mol. Genet. 29, R10–R18.
- 1048 28. Nguyen, T.-D., Harder, A., Xiong, Y., Kowalec, K., Hägg, S., Cai, N., Kuja-Halkola, R.,
- Dalman, C., Sullivan, P.F., and Lu, Y. (2022). Genetic heterogeneity and subtypes of major
 depression. Mol. Psychiatry 27, 1667–1675.
- 1051 29. Thorp, J.G., Marees, A.T., Ong, J.-S., An, J., MacGregor, S., and Derks, E.M. (2020).
- 1052 Genetic heterogeneity in self-reported depressive symptoms identified through genetic
- analyses of the PHQ-9. Psychol. Med. 50, 2385–2396.
- 1054 30. So, Y., Kim, K.W., Park, J.H., Lee, J.J., Lee, S.B., and TaeHui Kim (2012). P3-396:
- 1055 Anhedonia is associated with the risk of Alzheimer's disease in elders with mild cognitive
- impairment: Results from the Korean Longitudinal Study on Health and Aging (KLOSHA).
 Alzheimers Dement. 8, P594–P594.
- 1058 31. Lee, J.R., Suh, S.W., Han, J.W., Byun, S., Kwon, S.J., Lee, K.H., Kwak, K.P., Kim, B.J.,
- 1059 Kim, S.G., Kim, J.L., et al. (2019). Anhedonia and Dysphoria Are Differentially Associated

- 1060 with the Risk of Dementia in the Cognitively Normal Elderly Individuals: A Prospective 1061 Cohort Study. Psychiatry Investig 16, 575-580.
- 32. Vaquero-Puyuelo, D., De-la-Cámara, C., Olaya, B., Gracia-García, P., Lobo, A., López-1062
- 1063 Antón, R., and Santabárbara, J. (2021). Anhedonia as a Potential Risk Factor of Alzheimer's
- Disease in a Community-Dwelling Elderly Sample: Results from the ZARADEMP Project. 1064
- Int. J. Environ. Res. Public Health 18,. 1065
- 1066 33. Ikeda, M., Brown, J., Holland, A.J., Fukuhara, R., and Hodges, J.R. (2002). Changes in
- appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's 1067 disease. J. Neurol. Neurosurg. Psychiatry 73, 371-376. 1068
- 34. Bailon, O., Roussel, M., Boucart, M., Krystkowiak, P., and Godefroy, O. (2010). 1069
- Psychomotor slowing in mild cognitive impairment, Alzheimer's disease and lewy body 1070
- dementia: mechanisms and diagnostic value. Dement. Geriatr. Cogn. Disord. 29, 388-396. 1071
- 1072 35. Koren, T., Fisher, E., Webster, L., Livingston, G., and Rapaport, P. (2022). Prevalence of
- 1073 sleep disturbances in people with dementia living in the community: A systematic review and 1074 meta-analysis. Ageing Res Rev 101782.
- 36. Escott-Price, V., and Hardy, J. (2022). Genome-wide association studies for Alzheimer's 1075 1076 disease: bigger is not always better. Brain Commun. 4, fcac125.
- 1077 37. Marioni, R.E., Harris, S.E., Zhang, Q., McRae, A.F., Hagenaars, S.P., Hill, W.D., Davies,
- 1078 G., Ritchie, C.W., Gale, C.R., Starr, J.M., et al. (2018). GWAS on family history of
- 1079 Alzheimer's disease. Transl. Psychiatry 8, 99.
- 38. Liu, H., Hu, Y., Zhang, Y., Zhang, H., Gao, S., Wang, L., Wang, T., Han, Z., Sun, B.-L., 1080
- 1081 and Liu, G. (2022). Mendelian randomization highlights significant difference and genetic
- 1082 heterogeneity in clinically diagnosed Alzheimer's disease GWAS and self-report proxy 1083 phenotype GWAX. Alzheimers Res. Ther. 14, 17.
- 39. Desai, R., John, A., Saunders, R., Marchant, N.L., Buckman, J.E.J., Charlesworth, G., 1084
- 1085 Zuber, V., and Stott, J. (2023). Examining the Lancet Commission risk factors for dementia using Mendelian randomisation. BMJ Ment Health 26,. 1086
- 40. European Alzheimer's & Dementia Biobank Mendelian Randomization (EADB-MR) 1087
- 1088 Collaboration, Luo, J., Thomassen, J.O., Bellenguez, C., Grenier-Boley, B., de Rojas, I.,
- Castillo, A., Parveen, K., Küçükali, F., Nicolas, A., et al. (2023). Genetic associations 1089
- 1090 between modifiable risk factors and alzheimer disease. JAMA Netw. Open 6, e2313734.
- 41. Davies, M.R., Kalsi, G., Armour, C., Jones, I.R., McIntosh, A.M., Smith, D.J., Walters, 1091
- J.T.R., Bradley, J.R., Kingston, N., Ashford, S., et al. (2019). The Genetic Links to Anxiety 1092
- 1093 and Depression (GLAD) Study: Online recruitment into the largest recontactable study of 1094 depression and anxiety. Behav. Res. Ther. 123, 103503.
- 1095 42. Creese, B., Arathimos, R., Brooker, H., Aarsland, D., Corbett, A., Lewis, C., Ballard, C.,
- 1096 and Ismail, Z. (2021). Genetic risk for Alzheimer's disease, cognition, and mild behavioral 1097 impairment in healthy older adults. Alzheimers Dement (Amst) 13, e12164.
- 1098 43. Arathimos, R., Fabbri, C., Vassos, E., Davis, K.A.S., Pain, O., Gillett, A., Coleman,
- 1099 J.R.I., Hanscombe, K., Hagenaars, S., Jermy, B., et al. (2022). Latent subtypes of manic
- 1100 and/or irritable episode symptoms in two population-based cohorts. Br. J. Psychiatry 221, 1101 722-731.
- 44. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., 1102
- Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep 1103 1104 phenotyping and genomic data. Nature 562, 203-209.
- 1105 45. Wightman, D.P., Savage, J.E., Tissink, E., Romero, C., Jansen, I.E., and Posthuma, D.
- 1106 (2023). The genetic overlap between Alzheimer's disease, amyotrophic lateral sclerosis,
- 1107 Lewy body dementia, and Parkinson's disease. Neurobiol. Aging.
- 1108 46. Kroenke, K., Spitzer, R.L., and Williams, J.B. (2001). The PHQ-9: validity of a brief
- 1109 depression severity measure. J. Gen. Intern. Med. 16, 606-613.

- 1110 47. Sun, Y., Fu, Z., Bo, Q., Mao, Z., Ma, X., and Wang, C. (2020). The reliability and
- validity of PHQ-9 in patients with major depressive disorder in psychiatric hospital. BMCPsychiatry 20, 474.
- 1113 48. Mbatchou, J., Barnard, L., Backman, J., Marcketta, A., Kosmicki, J.A., Ziyatdinov, A.,
- 1114 Benner, C., O'Dushlaine, C., Barber, M., Boutkov, B., et al. (2021). Computationally
- efficient whole-genome regression for quantitative and binary traits. Nat. Genet. 53, 1097–
- **1116** 1103.
- 1117 49. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015).
- Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience4, 7.
- 50. Privé, F., Luu, K., Blum, M.G.B., McGrath, J.J., and Vilhjálmsson, B.J. (2020). Efficient
 toolkit implementing best practices for principal component analysis of population genetic
 data. Bioinformatics *36*, 4449–4457.
- 1123 51. McCarthy, S., Das, S., Kretzschmar, W., Delaneau, O., Wood, A.R., Teumer, A., Kang,
- H.M., Fuchsberger, C., Danecek, P., Sharp, K., et al. (2016). A reference panel of 64,976
- haplotypes for genotype imputation. Nat. Genet. 48, 1279–1283.
- 1126 52. Chou, W.-C., Zheng, H.-F., Cheng, C.-H., Yan, H., Wang, L., Han, F., Richards, J.B.,
- 1127 Karasik, D., Kiel, D.P., and Hsu, Y.-H. (2016). A combined reference panel from the
- 1000 Genomes and UK10K projects improved rare variant imputation in European andChinese samples. Sci. Rep. *6*, 39313.
- 1130 53. Taliun, D., Harris, D.N., Kessler, M.D., Carlson, J., Szpiech, Z.A., Torres, R., Taliun,
- 1131 S.A.G., Corvelo, A., Gogarten, S.M., Kang, H.M., et al. (2021). Sequencing of 53,831
- diverse genomes from the NHLBI TOPMed Program. Nature *590*, 290–299.
- 1133 54. 1000 Genomes Project Consortium, Auton, A., Brooks, L.D., Durbin, R.M., Garrison,
- 1134 E.P., Kang, H.M., Korbel, J.O., Marchini, J.L., McCarthy, S., McVean, G.A., et al. (2015). A
- 1135 global reference for human genetic variation. Nature *526*, 68–74.
- 1136 55. Murphy, A.E., Schilder, B.M., and Skene, N.G. (2021). MungeSumstats: A Bioconductor
- package for the standardisation and quality control of many GWAS summary statistics.Bioinformatics.
- 1139 56. Bulik-Sullivan, B., Loh, P.-R., Finucane, H.K., Ripke, S., Yang, J., Schizophrenia
- 1140 Working Group of the Psychiatric Genomics Consortium, Patterson, N., Daly, M.J., Price,
- 1141 A.L., and Neale, B.M. (2015). LD Score regression distinguishes confounding from
- 1142 polygenicity in genome-wide association studies. Nat. Genet. 47, 291–295.
- 1143 57. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.-R.,
- 1144 ReproGen Consortium, Psychiatric Genomics Consortium, Genetic Consortium for Anorexia
- 1145 Nervosa of the Wellcome Trust Case Control Consortium 3, Duncan, L., et al. (2015). An
- atlas of genetic correlations across human diseases and traits. Nat. Genet. 47, 1236–1241.
- 58. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis
 of genomewide association scans. Bioinformatics 26, 2190–2191.
- 1149 59. Turley, P., Walters, R.K., Maghzian, O., Okbay, A., Lee, J.J., Fontana, M.A., Nguyen-
- 1149 59. Turley, F., Walters, K.K., Magnzian, O., Okbay, A., Lee, J.J., Folitana, M.A., Nguyen-1150 Viet, T.A., Wedow, R., Zacher, M., Furlotte, N.A., et al. (2018). Multi-trait analysis of
- 1150 genome-wide association summary statistics using MTAG. Nat. Genet. 50, 229–237.
- 1152 60. Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional
- 1153 mapping and annotation of genetic associations with FUMA. Nat. Commun. 8, 1826.
- 1154 61. Jaffe, A.E., Straub, R.E., Shin, J.H., Tao, R., Gao, Y., Collado-Torres, L., Kam-Thong,
- 1155 T., Xi, H.S., Quan, J., Chen, Q., et al. (2018). Developmental and genetic regulation of the
- human cortex transcriptome illuminate schizophrenia pathogenesis. Nat. Neurosci. 21, 1117–
 1125.
- 1158 62. Wang, D., Liu, S., Warrell, J., Won, H., Shi, X., Navarro, F.C.P., Clarke, D., Gu, M.,
- 1159 Emani, P., Yang, Y.T., et al. (2018). Comprehensive functional genomic resource and

- 1160 integrative model for the human brain. Science 362,.
- 1161 63. Fromer, M., Roussos, P., Sieberts, S.K., Johnson, J.S., Kavanagh, D.H., Perumal, T.M.,
- 1162 Ruderfer, D.M., Oh, E.C., Topol, A., Shah, H.R., et al. (2016). Gene expression elucidates
- 1163 functional impact of polygenic risk for schizophrenia. Nat. Neurosci. 19, 1442–1453.
- 1164 64. Ramasamy, A., Trabzuni, D., Guelfi, S., Varghese, V., Smith, C., Walker, R., De, T., UK
- 1165 Brain Expression Consortium, North American Brain Expression Consortium, Coin, L., et al.
- 1166 (2014). Genetic variability in the regulation of gene expression in ten regions of the human
- 1167 brain. Nat. Neurosci. 17, 1418–1428.
- 1168 65. Westra, H.-J., Peters, M.J., Esko, T., Yaghootkar, H., Schurmann, C., Kettunen, J.,
- 1169 Christiansen, M.W., Fairfax, B.P., Schramm, K., Powell, J.E., et al. (2013). Systematic
- identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet.
 45, 1238–1243.
- 1172 66. Zhernakova, D.V., Deelen, P., Vermaat, M., van Iterson, M., van Galen, M., Arindrarto,
- 1173 W., van 't Hof, P., Mei, H., van Dijk, F., Westra, H.-J., et al. (2017). Identification of context-
- dependent expression quantitative trait loci in whole blood. Nat. Genet. 49, 139–145.
- 1175 67. Võsa, U., Claringbould, A., Westra, H.-J., Bonder, M.J., Deelen, P., Zeng, B., Kirsten, H.,
- 1176 Saha, A., Kreuzhuber, R., Kasela, S., et al. (2018). Unraveling the polygenic architecture of
- 1177 complex traits using blood eQTL meta-analysis. BioRxiv.
- 1178 68. Buil, A., Brown, A.A., Lappalainen, T., Viñuela, A., Davies, M.N., Zheng, H.-F.,
- 1179 Richards, J.B., Glass, D., Small, K.S., Durbin, R., et al. (2015). Gene-gene and gene-
- environment interactions detected by transcriptome sequence analysis in twins. Nat. Genet.
 47, 88–91.
- 1182 69. Ng, B., White, C.C., Klein, H.-U., Sieberts, S.K., McCabe, C., Patrick, E., Xu, J., Yu, L.,
- 1183 Gaiteri, C., Bennett, D.A., et al. (2017). An xQTL map integrates the genetic architecture of 1184 the human brain's transcriptome and epigenome. Nat. Neurosci. 20, 1418–1426.
- 1185 70. van Rheenen, W., Peyrot, W.J., Schork, A.J., Lee, S.H., and Wray, N.R. (2019). Genetic
- 1186 correlations of polygenic disease traits: from theory to practice. Nat. Rev. Genet. 20, 567–
- **1187** 581.
- 1188 71. Ning, Z., Pawitan, Y., and Shen, X. (2020). High-definition likelihood inference of
 1189 genetic correlations across human complex traits. Nat. Genet. *52*, 859–864.
- 1190 72. Werme, J., van der Sluis, S., Posthuma, D., and de Leeuw, C.A. (2022). An integrated
 1191 framework for local genetic correlation analysis. Nat. Genet. *54*, 274–282.
- 1192 73. Spargo, T.P., Gilchrist, L., Hunt, G.P., Dobson, R.J., Proitsi, P.P., Al-Chalabi, A., Pain,
- 1193 O., and Iacoangeli, A. (2023). Statistical examination of shared loci in neuropsychiatric
- 1194 diseases using genome-wide association study summary statistics. MedRxiv.
- 1195 74. Zou, Y., Carbonetto, P., Wang, G., and Stephens, M. (2022). Fine-mapping from
- summary data with the "Sum of Single Effects" model. PLoS Genet. 18, e1010299.
- 1197 75. Wallace, C. (2021). A more accurate method for colocalisation analysis allowing for
- 1198 multiple causal variants. PLoS Genet. 17, e1009440.
- 1199 76. Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace,
- 1200 C., and Plagnol, V. (2014). Bayesian test for colocalisation between pairs of genetic
- association studies using summary statistics. PLoS Genet. 10, e1004383.
- 1202 77. Sanderson, E., Glymour, M.M., Holmes, M.V., Kang, H., Morrison, J., Munafò, M.R.,
- Palmer, T., Schooling, C.M., Wallace, C., Zhao, Q., et al. (2022). Mendelian randomization.
 Nat. Rev. Methods Primers 2, 6.
- 78. Burgess, S., Davies, N.M., and Thompson, S.G. (2016). Bias due to participant overlap in
 two-sample Mendelian randomization. Genet. Epidemiol. 40, 597–608.
- 1207 79. Morrison, J., Knoblauch, N., Marcus, J.H., Stephens, M., and He, X. (2020). Mendelian
- 1208 randomization accounting for correlated and uncorrelated pleiotropic effects using genome-
- 1209 wide summary statistics. Nat. Genet. *52*, 740–747.

- 1210 80. Hemani, G., Bowden, J., and Davey Smith, G. (2018). Evaluating the potential role of
- 1211 pleiotropy in Mendelian randomization studies. Hum. Mol. Genet. 27, R195–R208.
- 1212 81. Slob, E.A.W., and Burgess, S. (2020). A comparison of robust Mendelian randomization
 1213 methods using summary data. Genet. Epidemiol. 44, 313–329.
- 1214 82. Bowden, J., Davey Smith, G., and Burgess, S. (2015). Mendelian randomization with
- 1215 invalid instruments: effect estimation and bias detection through Egger regression. Int. J.
- 1216 Epidemiol. 44, 512–525.
- 1217 83. Bowden, J., Davey Smith, G., Haycock, P.C., and Burgess, S. (2016). Consistent
- Estimation in Mendelian Randomization with Some Invalid Instruments Using a WeightedMedian Estimator. Genet. Epidemiol. 40, 304–314.
- 1220 84. Hartwig, F.P., Davey Smith, G., and Bowden, J. (2017). Robust inference in summary
- data Mendelian randomization via the zero modal pleiotropy assumption. Int. J. Epidemiol.
 46, 1985–1998.
- 1223 85. Verbanck, M., Chen, C.-Y., Neale, B., and Do, R. (2018). Detection of widespread
- horizontal pleiotropy in causal relationships inferred from Mendelian randomization between
 complex traits and diseases. Nat. Genet. *50*, 693–698.
- 1226 86. Burgess, S., and Thompson, S.G. (2017). Interpreting findings from Mendelian
- randomization using the MR-Egger method. Eur J Epidemiol *32*, 377–389.
- 1228 87. Burgess, S., Bowden, J., Fall, T., Ingelsson, E., and Thompson, S.G. (2017). Sensitivity
- Analyses for Robust Causal Inference from Mendelian Randomization Analyses with
 Multiple Genetic Variants. Epidemiology 28, 30–42.
- 1231 88. Lawlor, D.A., Harbord, R.M., Sterne, J.A.C., Timpson, N., and Davey Smith, G. (2008).
- 1232 Mendelian randomization: using genes as instruments for making causal inferences in
- 1233 epidemiology. Stat. Med. 27, 1133–1163.
- 1234 89. Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N.A., and
- 1235 Thompson, J.R. (2016). Assessing the suitability of summary data for two-sample Mendelian
- randomization analyses using MR-Egger regression: the role of the I2 statistic. Int. J.
 Epidemiol. 45, 1961–1974.
- 1238 90. Mahley, R.W. (2016). Apolipoprotein E: from cardiovascular disease to
- 1239 neurodegenerative disorders. J. Mol. Med. 94, 739–746.
- 1240 91. Liu, S., Liu, J., Weng, R., Gu, X., and Zhong, Z. (2019). Apolipoprotein E gene
- polymorphism and the risk of cardiovascular disease and type 2 diabetes. BMC Cardiovasc.Disord. *19*, 213.
- 1243 92. Xuan, L., Zhao, Z., Jia, X., Hou, Y., Wang, T., Li, M., Lu, J., Xu, Y., Chen, Y., Qi, L., et
- al. (2018). Type 2 diabetes is causally associated with depression: a Mendelian randomizationanalysis. Front Med *12*, 678–687.
- 1246 93. Lu, Y., Wang, Z., Georgakis, M.K., Lin, H., and Zheng, L. (2021). Genetic liability to
- 1247 depression and risk of coronary artery disease, myocardial infarction, and other
- 1248 cardiovascular outcomes. J. Am. Heart Assoc. 10, e017986.
- 1249 94. Lord, J., Jermy, B., Green, R., Wong, A., Xu, J., Legido-Quigley, C., Dobson, R.,
- 1250 Richards, M., and Proitsi, P. (2021). Mendelian randomization identifies blood metabolites
- 1251 previously linked to midlife cognition as causal candidates in Alzheimer's disease. Proc.
- 1252 Natl. Acad. Sci. USA *118*,.
- 1253 95. Choi, S.W., Mak, T.S.-H., and O'Reilly, P.F. (2020). Tutorial: a guide to performing
- 1254 polygenic risk score analyses. Nat. Protoc. 15, 2759–2772.
- 1255 96. Zhang, Q., Privé, F., Vilhjálmsson, B., and Speed, D. (2021). Improved genetic prediction
- 1256 of complex traits from individual-level data or summary statistics. Nat. Commun. *12*, 4192.
- 1257 97. Lovestone, S., Francis, P., Kloszewska, I., Mecocci, P., Simmons, A., Soininen, H.,
- 1258 Spenger, C., Tsolaki, M., Vellas, B., Wahlund, L.-O., et al. (2009). AddNeuroMed--the
- 1259 European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann.

- 1260 N. Y. Acad. Sci. 1180, 36–46.
- 1261 98. Lord, J., Green, R., Choi, S.W., Hübel, C., Aarsland, D., Velayudhan, L., Sham, P.,
- 1262 Legido-Quigley, C., Richards, M., Dobson, R., et al. (2022). Disentangling independent and
- mediated causal relationships between blood metabolites, cognitive factors, and alzheimer's
 disease. Biological Psychiatry Global Open Science 2, 167–179.
- 1265 99. Yang, J., Weedon, M.N., Purcell, S., Lettre, G., Estrada, K., Willer, C.J., Smith, A.V.,
- 1266 Ingelsson, E., O'Connell, J.R., Mangino, M., et al. (2011). Genomic inflation factors under
- 1267 polygenic inheritance. Eur. J. Hum. Genet. 19, 807–812.
- 1268 100. Voskobiynyk, Y., Roth, J.R., Cochran, J.N., Rush, T., Carullo, N.V., Mesina, J.S.,
- Waqas, M., Vollmer, R.M., Day, J.J., McMahon, L.L., et al. (2020). Alzheimer's disease risk
 gene BIN1 induces Tau-dependent network hyperexcitability. Elife 9,.
- 1271 101. Lambert, E., Saha, O., Soares Landeira, B., Melo de Farias, A.R., Hermant, X., Carrier,
- 1272 A., Pelletier, A., Gadaut, J., Davoine, L., Dupont, C., et al. (2022). The Alzheimer
- susceptibility gene BIN1 induces isoform-dependent neurotoxicity through early endosomedefects. Acta Neuropathol. Commun. 10, 4.
- 1275 102. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P.,
- Boehnke, M., Abecasis, G.R., and Willer, C.J. (2010). LocusZoom: regional visualization of
- 1277 genome-wide association scan results. Bioinformatics *26*, 2336–2337.
- 1278 103. Dashti, H.S., Daghlas, I., Lane, J.M., Huang, Y., Udler, M.S., Wang, H., Ollila, H.M.,
- Jones, S.E., Kim, J., Wood, A.R., et al. (2021). Genetic determinants of daytime napping andeffects on cardiometabolic health. Nat. Commun. *12*, 900.
- 1281 104. Jansen, P.R., Watanabe, K., Stringer, S., Skene, N., Bryois, J., Hammerschlag, A.R., de
- 1282 Leeuw, C.A., Benjamins, J.S., Muñoz-Manchado, A.B., Nagel, M., et al. (2019). Genome-
- wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional
 pathways. Nat. Genet. *51*, 394–403.
- 1285 105. Hammerschlag, A.R., Stringer, S., de Leeuw, C.A., Sniekers, S., Taskesen, E.,
- 1286 Watanabe, K., Blanken, T.F., Dekker, K., Te Lindert, B.H.W., Wassing, R., et al. (2017).
- 1287 Genome-wide association analysis of insomnia complaints identifies risk genes and genetic
- 1288 overlap with psychiatric and metabolic traits. Nat. Genet. 49, 1584–1592.
- 1289 106. Loos, R.J.F., and Yeo, G.S.H. (2022). The genetics of obesity: from discovery to
- 1290 biology. Nat. Rev. Genet. 23, 120–133.
- 1291 107. Zarza-Rebollo, J.A., Molina, E., and Rivera, M. (2021). The role of the FTO gene in the
- relationship between depression and obesity. A systematic review. Neurosci. Biobehav. Rev. *127*, 630–637.
- 1294 108. González, L.M., García-Herráiz, A., Mota-Zamorano, S., Flores, I., Albuquerque, D.,
- and Gervasini, G. (2021). Variants in the Obesity-Linked FTO gene locus modulates
- 1296 psychopathological features of patients with Anorexia Nervosa. Gene 783, 145572.
- 1297 109. Li, Y., Dang, X., Chen, R., Wang, J., Li, S., Mitchell, B.L., Yao, Y.-G., Li, M., Li, T.,
- 1298 Zhang, Z., et al. (2023). Cross-ancestry genome-wide association study and systems-level
- integrative analyses implicate new risk genes and therapeutic targets for depression.MedRxiv.
- 1301 110. Dall'Aglio, L., Lewis, C.M., and Pain, O. (2021). Delineating the genetic component of
 1302 gene expression in major depression. Biol. Psychiatry *89*, 627–636.
- 1303 111. Fabbri, C., Pain, O., Hagenaars, S.P., Lewis, C.M., and Serretti, A. (2021).
- 1304 Transcriptome-wide association study of treatment-resistant depression and depression
- 1305 subtypes for drug repurposing. Neuropsychopharmacology 46, 1821–1829.
- 1306 112. Koskinen, M.-K., and Hovatta, I. (2023). Genetic insights into the neurobiology of
- 1307 anxiety. Trends Neurosci. 46, 318–331.
- 1308 113. Nagel, M., Jansen, P.R., Stringer, S., Watanabe, K., de Leeuw, C.A., Bryois, J., Savage,
- 1309 J.E., Hammerschlag, A.R., Skene, N.G., Muñoz-Manchado, A.B., et al. (2018). Meta-analysis

- of genome-wide association studies for neuroticism in 449,484 individuals identifies novel
 genetic loci and pathways. Nat. Genet. 50, 920–927.
- 1312 114. Mallard, T.T., Linnér, R.K., Grotzinger, A.D., Sanchez-Roige, S., Seidlitz, J., Okbay,
- 1313 A., de Vlaming, R., Meddens, S.F.W., Bipolar Disorder Working Group of the Psychiatric
- 1314 Genomics Consortium, Palmer, A.A., et al. (2022). Multivariate GWAS of psychiatric
- disorders and their cardinal symptoms reveal two dimensions of cross-cutting genetic
- 1316 liabilities. Cell Genomics 2,.
- 1317 115. Lüningschrör, P., Werner, G., Stroobants, S., Kakuta, S., Dombert, B., Sinske, D.,
- 1318 Wanner, R., Lüllmann-Rauch, R., Wefers, B., Wurst, W., et al. (2020). The FTLD risk factor
- 1319 TMEM106B regulates the transport of lysosomes at the axon initial segment of motoneurons.1320 Cell Rep. *30*, 3506–3519.e6.
- 1321 116. Van Deerlin, V.M., Sleiman, P.M.A., Martinez-Lage, M., Chen-Plotkin, A., Wang, L.-
- 1322 S., Graff-Radford, N.R., Dickson, D.W., Rademakers, R., Boeve, B.F., Grossman, M., et al.
- (2010). Common variants at 7p21 are associated with frontotemporal lobar degeneration with
 TDP-43 inclusions. Nat. Genet. 42, 234–239.
- 1325 117. Nicholson, A.M., and Rademakers, R. (2016). What we know about TMEM106B in
- 1326 neurodegeneration. Acta Neuropathol. *132*, 639–651.
- 1327 118. Feng, T., Lacrampe, A., and Hu, F. (2021). Physiological and pathological functions of
- TMEM106B: a gene associated with brain aging and multiple brain disorders. ActaNeuropathol. *141*, 327–339.
- 1330 119. Perneel, J., and Rademakers, R. (2022). Identification of TMEM106B amyloid fibrils
- provides an updated view of TMEM106B biology in health and disease. Acta Neuropathol. *144*, 807–819.
- 1333 120. Mao, F., Robinson, J.L., Unger, T., Posavi, M., Amado, D.A., Elman, L., Grossman, M.,
- 1334 Wolk, D.A., Lee, E.B., Van Deerlin, V.M., et al. (2021). TMEM106B modifies TDP-43
- pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. Acta
- 1336 Neuropathol. *142*, 629–642.
- 1337 121. Vass, R., Ashbridge, E., Geser, F., Hu, W.T., Grossman, M., Clay-Falcone, D., Elman,
- 1338 L., McCluskey, L., Lee, V.M.Y., Van Deerlin, V.M., et al. (2011). Risk genotypes at
- 1339 TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta1340 Neuropathol. *121*, 373–380.
- 1341 122. Shafit-Zagardo, B., Sidoli, S., Goldman, J.E., DuBois, J.C., Corboy, J.R., Strittmatter,
- 1342 S.M., Guzik, H., Graff, S., and Nagra, R.M. (2022). TMEM106B is increased in Multiple
- 1343 Sclerosis plaques, and deletion causes accumulation of lipid after demyelination. BioRxiv.
- 1344 123. Hong, S., Dobricic, V., Ohlei, O., Bos, I., Vos, S.J.B., Prokopenko, D., Tijms, B.M.,
- 1345 Andreasson, U., Blennow, K., Vandenberghe, R., et al. (2021). TMEM106B and CPOX are
- 1346 genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimers1347 Dement. 17, 1628–1640.
- 1348 124. Dhiman, K., Gupta, V.B., Villemagne, V.L., Eratne, D., Graham, P.L., Fowler, C.,
- 1349 Bourgeat, P., Li, Q.-X., Collins, S., Bush, A.I., et al. (2020). Cerebrospinal fluid
- 1350 neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's
- 1351 disease. Alzheimers Dement (Amst) 12, e12005.
- 1352 125. Chen, M.-H., Liu, Y.-L., Kuo, H.-W., Tsai, S.-J., Hsu, J.-W., Huang, K.-L., Tu, P.-C.,
- 1353 and Bai, Y.-M. (2022). Neurofilament light chain is a novel biomarker for major depression
- and related executive dysfunction. Int. J. Neuropsychopharmacol. 25, 99–105.
- 1355 126. Brodaty, H., and Donkin, M. (2009). Family caregivers of people with dementia.
- 1356 Dialogues Clin Neurosci 11, 217–228.
- 1357 127. Lindeza, P., Rodrigues, M., Costa, J., Guerreiro, M., and Rosa, M.M. (2020). Impact of
- 1358 dementia on informal care: a systematic review of family caregivers' perceptions. BMJ
- 1359 Support. Palliat. Care.

- 1360 128. Victor, C.R., Rippon, I., Quinn, C., Nelis, S.M., Martyr, A., Hart, N., Lamont, R., and
- 1361 Clare, L. (2021). The prevalence and predictors of loneliness in caregivers of people with
- dementia: findings from the IDEAL programme. Aging Ment. Health 25, 1232–1238.
- 1363 129. Huang, S.-S. (2022). Depression among caregivers of patients with dementia:
- 1364 Associative factors and management approaches. World J. Psychiatry 12, 59–76.
- 1365 130. Chesney, E., Goodwin, G.M., and Fazel, S. (2014). Risks of all-cause and suicide
- 1366 mortality in mental disorders: a meta-review. World Psychiatry 13, 153–160.
- 1367 131. Fry, A., Littlejohns, T.J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins,
- 1368 R., and Allen, N.E. (2017). Comparison of Sociodemographic and Health-Related
- 1369 Characteristics of UK Biobank Participants With Those of the General Population. Am. J.1370 Epidemiol. *186*, 1026–1034.
- 1371 132. Brommelhoff, J.A., Gatz, M., Johansson, B., McArdle, J.J., Fratiglioni, L., and
- 1372 Pedersen, N.L. (2009). Depression as a risk factor or prodromal feature for dementia?
- 1373 Findings in a population-based sample of Swedish twins. Psychol. Aging 24, 373–384.
- 1374 133. Creese, B., and Ismail, Z. (2022). Mild behavioral impairment: measurement and
- 1375 clinical correlates of a novel marker of preclinical Alzheimer's disease. Alzheimers Res.
- 1376 Ther. *14*, 2.
- 1377 134. DeMichele-Sweet, M.A.A., Klei, L., Creese, B., Harwood, J.C., Weamer, E.A.,
- 1378 McClain, L., Sims, R., Hernandez, I., Moreno-Grau, S., Tárraga, L., et al. (2021). Genome-
- 1379 wide association identifies the first risk loci for psychosis in Alzheimer disease. Mol.
- 1380 Psychiatry 26, 5797–5811.
- 1381